<SEC-DOCUMENT>0001213900-25-075972.txt : 20250814
<SEC-HEADER>0001213900-25-075972.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250813212948
ACCESSION NUMBER:		0001213900-25-075972
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250813
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		251213860

	BUSINESS ADDRESS:	
		STREET 1:		2875 SOUTH OCEAN
		STREET 2:		SUITE 200
		CITY:			PALM BEACH
		STATE:			FL
		ZIP:			33480
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		2875 SOUTH OCEAN
		STREET 2:		SUITE 200
		CITY:			PALM BEACH
		STATE:			FL
		ZIP:			33480

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0252596-8k_180life.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:ATNF="http://180lifesciences.com/20250813">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_ATNF_180lifesciences.com_20250813 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20250813_20250813 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000004" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20250813.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-13</xbrli:startDate>
        <xbrli:endDate>2025-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-13</xbrli:startDate>
        <xbrli:endDate>2025-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-13</xbrli:startDate>
        <xbrli:endDate>2025-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pc; margin-bottom: 0pc; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM <span id="xdx_905_edei--DocumentType_c20250813__20250813_zBu4xJSHgUR7"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date of
earliest event reported): <span id="xdx_904_edei--DocumentPeriodEndDate_c20250813__20250813_zKpUUJbhDl4d"><ix:nonNumeric contextRef="AsOf2025-08-13" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 13, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20250813__20250813_zhZoeLCSPV7f"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000011" name="dei:EntityRegistrantName">180 LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20250813__20250813_zxEjJStnzLAk"><ix:nonNumeric contextRef="AsOf2025-08-13" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><b><span id="xdx_904_edei--EntityFileNumber_c20250813__20250813_zP8IQaHEt0wi"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000013" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20250813__20250813_zLVsBc4Ac9w9"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000014" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(State or Other Jurisdiction<br/>
of Incorporation)</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer<br/>
Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><b></b><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20250813__20250813_zkcT3Itlu6jf"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000015" name="dei:EntityAddressAddressLine1">2875 South Ocean</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20250813__20250813_z9OU273eOz71"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b> <b><br/>
<span id="xdx_90F_edei--EntityAddressCityOrTown_c20250813__20250813_zUwUQlO0GLFe"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000017" name="dei:EntityAddressCityOrTown">Palm Beach</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250813__20250813_zPV4F3U3pWak"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000018" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b> <b></b></td>
    <td style="vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20250813__20250813_zN33MYZJsBu3"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000019" name="dei:EntityAddressPostalZipCode">33480</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of Principal Executive Offices)</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code: <b><span style="text-decoration: underline">(<span id="xdx_906_edei--CityAreaCode_c20250813__20250813_zkdctbRCc5qd"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000020" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20250813__20250813_zWiByQIiheu3"><ix:nonNumeric contextRef="AsOf2025-08-13" id="Fact000021" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see </i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--WrittenCommunications_c20250813__20250813_z0pGQ2976fX5"><ix:nonNumeric contextRef="AsOf2025-08-13" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--SolicitingMaterial_c20250813__20250813_zn0eRnVsv52j"><ix:nonNumeric contextRef="AsOf2025-08-13" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--PreCommencementTenderOffer_c20250813__20250813_zq9BxwdYbjN1"><ix:nonNumeric contextRef="AsOf2025-08-13" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20250813__20250813_zJx53xgcnZr5"><ix:nonNumeric contextRef="AsOf2025-08-13" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Title of each class</b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b>Trading Symbol(s)</b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_90A_edei--Security12bTitle_c20250813__20250813__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zMyhK4F2z0I8"><ix:nonNumeric contextRef="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span id="xdx_906_edei--TradingSymbol_c20250813__20250813__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zaA0hvLOGpTf"><ix:nonNumeric contextRef="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">The <span id="xdx_904_edei--SecurityExchangeName_c20250813__20250813__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z1O5tH6EK0Tl"><ix:nonNumeric contextRef="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span id="xdx_90A_edei--Security12bTitle_c20250813__20250813__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_z3BvdXjxbKHb"><ix:nonNumeric contextRef="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000029" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span id="xdx_906_edei--TradingSymbol_c20250813__20250813__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zFN44fplcaU8"><ix:nonNumeric contextRef="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000030" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">The <span id="xdx_900_edei--SecurityExchangeName_c20250813__20250813__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zBw4CcUxQoFe"><ix:nonNumeric contextRef="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company
<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20250813__20250813_zvLlaSnkAzn5"><ix:nonNumeric contextRef="AsOf2025-08-13" format="ixt:booleanfalse" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pc; margin-bottom: 0pc; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sales Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 13, 2025, 180 Life Sciences Corp. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
entered into a Sales Agreement (the &#8220;<span style="text-decoration: underline">Sales Agreement</span>&#8221;) to sell shares of the Company&#8217;s common stock, par value
$0.0001 per share (the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;) from time to time through Clear Street LLC (the &#8220;<span style="text-decoration: underline">Agent</span>&#8221;),
acting as sales agent. Pursuant to the prospectus supplement dated August 13, 2025 (the &#8220;<span style="text-decoration: underline">Prospectus Supplement</span>&#8221;)
filed by the Company with the Securities and Exchange Commission (&#8220;<span style="text-decoration: underline">SEC&#8221;</span>), which supplements the base prospectus included
in the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-288194), initially filed with the SEC on June 20, 2025 and
declared effective on June 26, 2025 (the &#8220;<span style="text-decoration: underline">Registration Statement</span>&#8221;), the Company will be able to offer and sell up to
$500,000,000 of its shares of Common Stock through the Agent pursuant to the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon delivery of a placement notice and subject to the terms and conditions
of the Sales Agreement, the Agent may sell the Common Stock in negotiated transactions or transactions that are deemed to be an &#8220;at
the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221;), including sales made directly on the principal market on which the Common Stock is listed or any other existing trading
market for the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will designate the maximum amount of Common Stock to be
sold through the Agent in any placement under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, the Agent
has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations,
to sell on the Company&#8217;s behalf all of the shares of Common Stock requested to be sold by the Company. The Company may instruct
the Agent not to sell Common Stock if the sales cannot be effected at or above a price designated by the Company in a placement notice.
The Company or the Agent may suspend the offering of Common Stock pursuant to the Sales Agreement upon proper notice to the other party.
The Company and the Agent each have the right, by giving 10 days&#8217; notice as specified in the Sales Agreement, to terminate the Sales
Agreement in each party&#8217;s sole discretion at any time. The Agent, subject to mutual agreement between the Agent and the Company,
may also sell shares of Common Stock sold to it as principal by any other method permitted by law, including, but not limited to, privately
negotiated transactions and block trades. The Company also may sell shares of Common Stock to the Agent as principal for its own account,
at a price agreed upon at the time of sale. If the Company sells Common Stock to the Agent as principal, it will enter into a separate
terms agreement setting forth the terms of such transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agreement provides that the Agent will be entitled to aggregate
compensation for its services of up to 3.0% of the gross sales price per share of all shares sold through the Agent under the Sales Agreement.
The Company has no obligation to sell any shares under the Sales Agreement. In addition, the Company has agreed to reimburse certain legal
expenses incurred by the Agent in connection with execution of the Sales Agreement in an amount up to $75,000, in addition to certain
ongoing legal expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agreement contains customary representations, warranties
and covenants by the Company. The Company also agreed to provide indemnification and contribution to the Agent against certain liabilities,
including under the Securities Act and the Securities Exchange Act of 1934, as amended. From time to time, in the ordinary course of business,
the Agent has provided, and in the future may provide, various financial advisory and investment banking services to the Company, for
which they have received or will receive customary fees and reimbursement of expenses. The Agent acted as placement agent in connection
with the Company&#8217;s previously disclosed private placement of approximately $425 million of Common Stock and pre-funded warrants,
which closed on August 4, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any sales of shares of Common Stock under the Sales Agreement will
be made pursuant to the Registration Statement, and any applicable prospectus supplements that form a part of the Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of certain provisions of the Sales Agreement
is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit
1.1 to this Current Report on Form 8-K (the &#8220;<span style="text-decoration: underline">Current Report</span>&#8221;) and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The legal opinion of The Loev Law Firm, PC relating to the validity
of the shares of Common Stock to be sold pursuant to the Sales Agreement is filed as Exhibit 5.1 to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report shall not constitute an offer to sell or the solicitation
of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of the Common Stock in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 3.02 Unregistered
Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 11, 2025, a
holder of warrants to purchase 1,749 shares of common stock of the Company, with an exercise price of $2.65 per share, and 100,000 shares
of common stock of the Company, with an exercise price of $2.28 per share, exercised such warrants for cash, and such shares are in the
process of being issued as of the date of this Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The exercise of the warrants
were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, since the foregoing did not involve
a public offering and the holder was an accredited investor. The resale of the shares of common stock issuable upon exercise of the warrants
discussed above have been registered under the Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 9%"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 90%"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>1.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea025259601ex1-1_180life.htm">Sales Agreement, dated August 13, 2025, by and between 180 Life Sciences Corp. and Clear Street LLC</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>5.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea025259601ex5-1_180life.htm">Opinion of The Loev Law Firm, PC</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>23.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea025259601ex5-1_180life.htm">Consent of The Loev Law Firm, PC (included in Exhibit 5.1)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">104</td>
    <td>&#160;</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date: August 13, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><b>180 LIFE SCIENCES CORP.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt"><i>/s/ Blair Jordan</i></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 4%">Name:&#160; </td>
    <td style="width: 33%">Blair Jordan</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td>Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kdFOwjAUhp+AdzhZvCTQLlHJ7nRBYgRdkKC3x3EmC1vPctohPJJvaddB5EKbJk17zvf//0mjaBjN+KGsSOD9fjmHFdVNhY5gSQUJmZx8R/r4lIA/l/RZWidoXLiewZQ9Q565GWn076FzX1raJKAmY63G8TWo20RNIFtEg66esinKDRlXYgVoNpAJN1KSQzn2Cis8sOH6GJzWJLZkk4Aeqb78DbHSMTzzHr9Ydhbm8zQaDMMaRDPhtvFd04Mj05Ewraj2dranf3dIk7fWcZ28oXSz2RVnreRbtPS6RSH7UvgJazavjvPdguoPEg9pFcda3Z3ynFlwDM2JBhtw4AJ6AQgKfzhf6Gcoa6xaUiOllM5IQoZ/XC9lh9CgwL5j4aqnofG/E0KcPX8ABI2V1Q== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea025259601ex1-1_180life.htm
<DESCRIPTION>SALES AGREEMENT, DATED AUGUST 13, 2025, BY AND BETWEEN 180 LIFE SCIENCES CORP. AND CLEAR STREET LLC
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">180 life sciences
corp.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>SALES AGREEMENT<BR>
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-weight: normal; text-decoration: none; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-weight: normal; text-transform: none">August
13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clear Street LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4 World Trade Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp., a
Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), confirms its agreement (this &#8220;<B><I>Agreement</I></B>&#8221;) with
Clear Street LLC (&#8220;<B><I>Clear Street</I></B>&#8221;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <I>Issuance
and Sale of Shares.</I> The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the
conditions set forth herein and any Terms Agreement (as defined below), it may issue and sell to or through Clear Street, acting as agent
and/or principal, shares (the &#8220;<B><I>Shares</I></B>&#8221;) of common stock, par value $0.0001 per share (the &#8220;<B><I>Common
Shares</I></B>&#8221;). The issuance and sale of Shares through Clear Street will be effected pursuant to the Registration Statement (as
defined below). The Company acknowledges and agrees that sales of Shares under this Agreement may be made through affiliates of Clear
Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has filed, in
accordance with the provisions of the Securities Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;), and the rules
and regulations thereunder (the &#8220;<B><I>Rules and Regulations</I></B>&#8221;), with the U.S. Securities and Exchange Commission (the
&#8220;<B><I>Commission</I></B>&#8221;), a registration statement on Form S-3 (File No. 333-288194), including a base prospectus, relating
to certain securities, including the Common Shares, to be issued from time to time by the Company, and which incorporates by reference
documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended
(the &#8220;<B><I>Exchange Act</I></B>&#8221;), and the rules and regulations thereunder (the &#8220;<B><I>Exchange Act Rules and Regulations</I></B>&#8221;).
The Company has prepared a prospectus supplement specifically relating to the Shares (the &#8220;<B><I>Prospectus Supplement</I></B>&#8221;)
to the base prospectus included as part of such registration statement. The Company has furnished to Clear Street, for use by Clear Street,
copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement. Except where the
context otherwise requires, such registration statement, and any post-effective amendment thereto, as amended when it became effective,
including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus
(as defined below) subsequently filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations or deemed to be a part
of such registration statement pursuant to Rule 430B or 462(b) of the Rules and Regulations, or any subsequent registration statement
on Form S-3 filed pursuant to Rule 415(a)(6) under the Securities Act by the Company with respect to the Shares, is herein called the
&#8220;<B><I>Registration Statement</I></B>.&#8221; Any registration statement and amendments thereto filed pursuant to Rule 462(b) of
the Securities Act and relating to the offering covered by the Registration Statement is herein called a &#8220;<B><I>Rule 462(b) Registration
Statement</I></B>&#8221; and, after such filing, the &#8220;Registration Statement&#8221; shall include any Rule 462(b) Registration Statement.
The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented
by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company
with the Commission pursuant to Rule 424(b) of the Rules and Regulations, together with any &#8220;issuer free writing prospectus,&#8221;
as defined in Rule 433 of the Rules and Regulations (&#8220;<B><I>Rule 433</I></B>&#8221;), relating to the Shares that (i) is consented
to by Clear Street in writing (including any free writing prospectus prepared by the Company solely for use in connection with the offering
contemplated by a particular Terms Agreement) (hereinafter referred to as a &#8220;<B><I>Permitted Free Writing Prospectus</I></B>&#8221;),
(ii) is required to be filed with the Commission by the Company or (iii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each
case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#8217;s
records pursuant to Rule 433(g), is herein called the &#8220;<B><I>Prospectus</I></B>.&#8221; Any reference herein to the Registration
Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by
reference therein, and any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with
respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof
of any document with the Commission deemed to be incorporated by reference therein. For purposes of this Agreement, all references to
the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the
Commission pursuant to the Electronic Data Gathering Analysis and Retrieval System (&#8220;<B><I>EDGAR</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <I>Agency
and Principal Transactions.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   Each
time that the Company wishes to issue and sell Shares hereunder through Clear Street, acting as agent (each, an &#8220;<B><I>Agency Transaction</I></B>&#8221;),
it will notify Clear Street by email notice (or other method mutually agreed to in writing by the parties) (a &#8220;<B><I>Placement Notice</I></B>&#8221;)
containing the parameters in accordance with which it desires the Shares to be sold, which shall at a minimum include the number of Shares
to be issued, the time period during which sales are requested to be made, any limitation on the number of Shares that may be sold in
any one Trading Day (as defined in Section 3) and any minimum price below which sales may not be made, a form of which containing such
minimum sales parameters necessary is attached hereto as <U>Schedule 1</U>. The Placement Notice shall originate from any of the individuals
from the Company set forth on <U>Schedule 2</U> (with a copy to each of the other individuals from the Company listed on such schedule),
and shall be addressed to each of the individuals from Clear Street set forth on <U>Schedule 2</U>, as such <U>Schedule 2</U> may be amended
from time to time. The Placement Notice shall be effective upon receipt by Clear Street unless and until (i) in accordance with the notice
requirements set forth in Section 4, Clear Street declines in writing to accept the terms contained therein for any reason, in its sole
discretion, (ii) the entire amount of the Shares have been sold, (iii) in accordance with the notice requirements set forth in Section
4, the Company suspends, amends, supersedes, or terminates the Placement Notice for any reason, in its sole discretion, (iv) the Company
issues a subsequent Placement Notice with parameters superseding those on the earlier dated Placement Notice, or (v) this Agreement has
been terminated under the provisions of Section 11. The amount of any discount, commission or other compensation to be paid by the Company
to Clear Street in connection with the sale of Shares shall be calculated in accordance with the terms set forth in <U>Schedule 3</U>.
It is expressly acknowledged and agreed that neither the Company nor Clear Street will have any obligation whatsoever with respect to
an Agency Transaction or any Shares to be placed as part thereof unless and until the Company delivers a Placement Notice to Clear Street
and Clear Street does not decline (and the Company does not suspend or terminate) such Placement Notice pursuant to the terms set forth
above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the
terms of a Placement Notice, the terms of the Placement Notice will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   The
Company may also offer to sell the Shares directly to Clear Street, as principal, in which event such parties shall enter into a separate
agreement (each, a &#8220;<B><I>Terms Agreement</I></B>&#8221;) in substantially the form of Schedule 2(b) hereto (with such changes thereto
as may be agreed upon by the Company and Clear Street), relating to such sale in accordance with Section 3(b) hereof (each such transaction
being referred to as a &#8220;<B><I>Principal Transaction</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   Under
no circumstances shall the Company cause or request the offer or sale of any Shares if, after giving effect to the sale of such Shares,
the aggregate number or gross sales proceeds of Shares sold pursuant to this Agreement would exceed the lesser of: (a) the number or dollar
amount of Common Shares registered pursuant to, and available for offer and sale under, the Registration Statement pursuant to which the
offering of Shares is being made, (b) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise,
conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital
stock), (c) the number or dollar amount of Common Shares permitted to be offered and sold by the Company under Form S-3 (including General
Instruction I.B.6. thereof, if such instruction is applicable), (d) the number or dollar amount of Common Shares that the Company&#8217;s
board of directors or a duly authorized committee thereof is authorized to issue and sell from time to time, or (e) the dollar amount
of Common Shares for which the Company has filed a Prospectus (the lesser of (a)-(e), the &#8220;<B><I>Maximum Amount</I></B>&#8221;).
Under no circumstances shall the Company cause or request the offer or sale of any Shares pursuant to this Agreement at a price lower
than the minimum price authorized from time to time by the Company&#8217;s board of directors or a duly authorized committee thereof.
Notwithstanding anything to the contrary contained herein, the parties hereto acknowledge and agree that compliance with the limitations
set forth in this Section 2 on the number or dollar amount of Shares that may be issued and sold under this Agreement or any Terms Agreement
from time to time shall be the sole responsibility of the Company, and that Clear Street shall have no obligation in connection with such
compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <I>Sale
of Shares by Clear Street.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   Subject
to the terms and conditions herein set forth, upon the Company&#8217;s delivery of a Placement Notice with respect to an Agency Transaction,
and unless the sale of the Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms
of this Agreement, Clear Street, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent
with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital
Market (or any successor principal market on which the Common Shares are listed or quoted, the &#8220;<B><I>Exchange</I></B>&#8221;) to
sell such Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. Clear Street may sell
Shares in an Agency Transaction (A) in privately negotiated transactions with the consent of the Company; (B) as block transactions; or
(C) by any other method permitted by law deemed to be &#8220;at the market&#8221; offering as defined in Rule 415 of the Rules and Regulations,
including without limitation sales made through the Exchange or on any other existing trading market for the Common Shares. Clear Street
will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth
on <U>Schedule 2</U>) no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it
has made sales of Shares hereunder setting forth the number of Shares sold on such day, the volume-weighted average price of the Shares
sold, and the Net Proceeds (as defined below) payable to the Company. In the event the Company engages Clear Street for a sale of Shares
in an Agency Transaction that would constitute a &#8220;block&#8221; within the meaning of Rule 10b-18(a)(5) of the Exchange Act Rules
and Regulations, the Company will provide Clear Street, at Clear Street&#8217;s request and upon reasonable advance notice to the Company,
on or prior to the Settlement Date (as defined below), the opinions of counsel, accountant&#8217;s letter and officers&#8217; certificates
set forth in Section 8, each dated the Settlement Date, and such other documents and information as Clear Street shall reasonably request.
Clear Street shall not purchase Shares for its own account as principal unless expressly authorized to do so by the Company in a Terms
Agreement. The Company acknowledges and agrees that (i) there can be no assurance that Clear Street will be successful in selling Shares,
and (ii) Clear Street will incur no liability or obligation to the Company or any other person or entity if it does not sell Shares for
any reason other than a failure by Clear Street to use its commercially reasonable efforts consistent with its normal trading and sales
practices to sell such Shares as required under this Section 3. For the purposes hereof, &#8220;<B><I>Trading Day</I></B>&#8221; means
any day on which the Company&#8217;s Common Shares are purchased and sold on the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)(i) If the Company wishes
to issue and sell the Shares to Clear Street pursuant to this Agreement in a Principal Transaction, it will notify Clear Street of the
proposed terms of the Principal Transaction. If Clear Street, acting as principal, wishes to accept such proposed terms (which it may
decline to do for any reason in its sole discretion) or, following discussions with the Company, wishes to accept amended terms, the Company
and Clear Street shall enter into a Terms Agreement setting forth the terms of such Principal Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) The terms set forth in
a Terms Agreement shall not be binding on the Company or Clear Street unless and until the Company and Clear Street have each executed
and delivered such Terms Agreement accepting all of the terms of such Terms Agreement. In the event of a conflict between the terms of
this Agreement and the terms of a Terms Agreement, the terms of such Terms Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) Each sale of the Shares
to Clear Street in a Principal Transaction shall be made in accordance with the terms of this Agreement and a Terms Agreement, which shall
provide for the sale of such Shares to, and the purchase thereof by, Clear Street. A Terms Agreement may also specify certain provisions
relating to the reoffering of such Shares by Clear Street. The commitment of Clear Street to purchase the Shares pursuant to any Terms
Agreement shall be deemed to have been made on the basis of the representations, warranties and agreements of the Company contained, and
shall be subject to the terms and conditions set forth, in this Agreement and such Terms Agreement. Any such Terms Agreement shall specify
the number of the Shares to be purchased by Clear Street pursuant thereto, the price to be paid to the Company for such Shares, any provisions
relating to rights of, and default by, Clear Street in the reoffering of the Shares, and the time, date (each such time and date being
referred to herein as a &#8220;<B><I>Principal Settlement Date</I></B>&#8221;) and place of delivery of and payment for such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   Notwithstanding
any other provision of this Agreement, the Company shall not offer, sell or deliver, or request the offer or sale, of any Shares pursuant
to this Agreement (whether in an Agency Transaction or a Principal Transaction) and, by notice to Clear Street given by telephone (confirmed
promptly by email), shall cancel any instructions for the offer or sale of any Shares, and Clear Street shall not be obligated to offer
or sell any Shares, (i) during any period in which the Company is, or could be deemed to be, in possession of material non-public information,
or (ii) at any time from and including the date on which the Company shall issue a press release containing, or shall otherwise publicly
announce, its earnings, revenues or other results of operations (an &#8220;<B><I>Earnings Announcement</I></B>&#8221;) through and including
the time that the Company files a Quarterly Report on Form 10-Q or an Annual Report on Form 10-K that includes consolidated financial
statements as of and for the same period or periods, as the case may be, covered by such Earnings Announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <I>Suspension
of Sales. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   The
Company or Clear Street may, upon notice to the other party in writing (including by email correspondence to each of the individuals of
the other party set forth on <U>Schedule 2</U>, if receipt of such correspondence is actually acknowledged by any of the individuals to
whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by email correspondence to each of the individuals
of the other party set forth on <U>Schedule 2</U>), suspend any sale of Shares; <I>provided, however</I>, that such suspension shall not
affect or impair either party&#8217;s obligations with respect to any Shares sold hereunder prior to the receipt of such notice. Each
of the parties agrees that no such notice under this Section 4 shall be effective against the other unless it is made to one of the individuals
named on <U>Schedule 2</U>, as such schedule may be amended in writing from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   If
either Clear Street or the Company has reason to believe that the exemptive provisions set forth in Rule 101(c)(1) of Regulation M under
the Exchange Act are not satisfied with respect to the Common Shares, it shall promptly notify the other party, and Clear Street may,
at its sole discretion, suspend sales of the Shares under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   Notwithstanding
any other provision of this Agreement, during any period in which the Registration Statement is no longer effective under the Securities
Act, the Company shall promptly notify Clear Street, the Company shall not request the sale of any Shares, and Clear Street shall not
be obligated to sell or offer to sell any Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <I>Settlement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Settlement
of Shares</U>. Unless otherwise agreed in writing between the parties with respect to any Placement, settlement for sales of Shares in
an Agency Transaction will occur on the Trading Day following the date on which such sales are made (each, an &#8220;<B><I>Agency Settlement
Date</I></B>&#8221;; the earlier of the first such Agency Settlement Date and the first Principal Settlement Date, the &#8220;<B><I>First
Delivery Date</I></B>&#8221;; and any Agency Settlement Date and Principal Settlement Date, a &#8220;<B><I>Settlement Date</I></B>&#8221;).
The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Shares sold (the &#8220;<B><I>Net Proceeds</I></B>&#8221;)
will be equal to the aggregate sales price received by Clear Street at which such Shares were sold, after deducting (i)&nbsp;Clear Street&#8217;s
commission, discount or other compensation for such sales payable by the Company pursuant to Section 2 or pursuant to any applicable Terms
Agreement, (ii) any other amounts due and payable by the Company to Clear Street hereunder pursuant to Section 7(f) (Expenses), and (iii)
any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Delivery of
Shares</U>. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares
being sold by crediting Clear Street&#8217;s or its designee&#8217;s account (provided Clear Street shall have given the Company written
notice of such designee prior to the Settlement Date) at The Depository Trust Company through its Deposit/Withdrawal at Custodian system
or by such other means of delivery as may be mutually agreed upon by the parties, which in all cases shall be freely tradeable, transferable,
registered shares in good deliverable form. On each Settlement Date, Clear Street will deliver the related Net Proceeds in same day funds
to an account designated by the Company prior to the Settlement Date. The Company agrees that if the Company (or its transfer agent, if
applicable) defaults on its obligation to deliver Shares on a Settlement Date, in addition to and in no way limiting the rights and obligations
set forth in Section 9(a) (Indemnification and Contribution), it will (i)&nbsp;hold Clear Street harmless against any loss, claim, damage,
or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company
and (ii) pay to Clear Street any commission, discount, or other compensation to which it would otherwise have been entitled absent such
default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. <I>Representations
and Warranties of the Company.</I> The Company represents and warrants to, and agrees with, Clear Street that as of (i) the date of this
Agreement, (ii) each date on which the Company executes and delivers a Terms Agreement, (iii) the date and time of each sale of any Shares
pursuant to this Agreement (each of clauses (ii) and (iii), a &#8220;<B><I>Time of Sale</I></B>&#8221;), (iv) each Settlement Date, and
(v) each Bring-Down Date (as defined below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Compliance
with Registration Requirements</U>. The Registration Statement has become, prior to the first Time of Sale, effective under the Securities
Act. The Company has complied to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental
information. The Company meets the requirements for use of Form S&#45;3 under the Securities Act. The sale of the Shares hereunder meets
the requirements of General Instruction I.B.1. of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)  <U>No Misstatement
or Omission</U>. At the respective times the Registration Statement and any amendments thereto became or become effective as to Clear
Street, the Registration Statement and any amendments thereto conformed or will conform in all material respects to the requirements of
the Securities Act and the Rules and Regulations and did not or will not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendments
or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was or will be issued, conformed or will conform
in all material respects to the requirements of the Securities Act and the Rules and Regulations and did not or will not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were or will be made, not misleading. The foregoing representations and warranties in this paragraph (b) shall not apply
to information contained in or omitted from the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance
upon, and in conformity with, the Clear Street Information (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>No Stop Orders</U>.
No stop order suspending the effectiveness of the Registration Statement, nor any order preventing or suspending the use of the Prospectus,
has been issued and no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been initiated or threatened by
the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Documents
Incorporated by Reference</U>. The documents incorporated by reference in the Registration Statement and the Prospectus, when they were
filed with the Commission (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing),
conformed in all material respects to the requirements of the Exchange Act Rules and Regulations and none of such documents contained
an untrue statement of a material fact or omitted to state a material fact required to be stated therein, or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated
by reference in the Registration Statement or the Prospectus, when such documents are filed with Commission, will conform in all material
respects to the requirements of the Exchange Act and the Exchange Act Rules and Regulations and will not contain an untrue statement of
a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading. The foregoing representations and warranties in this paragraph (d) shall
not apply to information contained in or omitted from the Registration Statement, the Prospectus, or any amendment or supplement thereto,
in reliance upon, and in conformity with, the Clear Street Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Distribution
of Offering Materials</U>. The Company has not, directly or indirectly, distributed and will not distribute any offering material in connection
with the offering and sale of the Shares other than the Registration Statement or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Not an Ineligible
Issuer</U>. The Company currently is not an &#8220;ineligible issuer,&#8221; as defined in Rule 405 of the Rules and Regulations. The
Company agrees to notify Clear Street promptly if the Company becomes an &#8220;ineligible issuer.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Organization and
Good Standing</U>. The Company, 180 SPV Treasury Vehicle I, LLC and 180 Life Corp. (which are the only &ldquo;significant
subsidiaries&rdquo; (as defined under Rule 1-02 of Regulation S-X) of the Company as of the date of this Agreement) have been duly
organized and are validly existing as corporations or other legal entities in good standing (or the foreign equivalent thereof)
under the laws of their respective jurisdictions of organization. The Company, 180 SPV Treasury Vehicle I, LLC and 180 Life Corp.
are duly qualified to do business and are in good standing as foreign corporations or other legal entities in each jurisdiction in
which such qualification is required and have all power and authority (corporate or other) necessary to own or hold their respective
properties and to conduct the businesses in which they are engaged, except where the failure to so qualify or have such power or
authority would not have a Material Adverse Effect. For purposes of this Agreement, &#8220;<B><I>Material Adverse
Effect</I></B>&#8221; means any change, event, circumstance, development, condition, occurrence or effect that, individually or in
the aggregate, (i) was, is, or would reasonably be expected to be, materially adverse to the business, financial condition,
properties, assets, liabilities, stockholders&#8217; equity or results of operations of the Company and its subsidiaries, taken as a
whole, (ii) would result in a materially adverse effect on the legality, validity or enforceability of this Agreement or (iii)
materially delay or materially impair the ability of the Company to perform, or prevents the Company from performing, with its
obligations under this Agreement or to consummate any transactions contemplated by this Agreement or the Prospectus. The Company
does not own or control, directly or indirectly, any corporation, association or other entity other than those listed in
Exhibit&nbsp;21.1 to the Company&#8217;s Annual Report on Form&nbsp;10-K for the most recently ended fiscal year and other than
(i)&nbsp;those subsidiaries not required to be listed on Exhibit&nbsp;21.1 by Item&nbsp;601 of Regulation S-K under the Exchange Act
and (ii)&nbsp;those subsidiaries formed since the last day of the most recently ended fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) <U>The Sales
Agreement; Terms Agreement</U>. The Company has corporate power and authority to enter into and perform its obligations under this Agreement
and any Terms Agreement and to consummate the transactions contemplated herein and therein. This Agreement has been duly authorized, executed
and delivered by the Company. Any Terms Agreement will have been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) <U>The Shares</U>.
The Shares to be issued and sold by the Company hereunder have been duly and validly authorized and, when issued and delivered against
payment therefor as provided in this Agreement or any Terms Agreement, (i) will be duly and validly issued, fully paid and non-assessable,
(ii) will be free and clear of any pledge, lien, encumbrance, security interest or other claim, and (iii) will conform to the descriptions
thereof in the Registration Statement and the Prospectus. The issuance of the Shares will not, (a) obligate the Company to offer to issue,
or issue, Common Shares or other securities to any person pursuant to any preemptive rights, rights of first refusal, rights of participation
or similar rights, or (b) result in any adjustment (automatic, at the election of any person or otherwise) of the exercise, conversion,
exchange or reset price under, or any other anti-dilution adjustment pursuant to, any outstanding securities of the Company or (c) be
subject to any preemptive right, right of first offer, or any similar right of any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) <U>Capitalization</U>.
The Company&#8217;s disclosure of its authorized, issued and outstanding capital stock in the Prospectus is accurate in all material respects
as of the date indicated therein. All of the issued and outstanding Common Shares have been duly authorized and validly issued and are
fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive
or other similar rights of any securityholder of the Company which have not been waived, and such shares were issued in compliance in
all material respects with applicable state and federal securities law and any rights of third parties. Except as disclosed in the Prospectus,
there are no outstanding rights (including, without limitation, pre-emptive or other similar rights), warrants or options to acquire,
or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its
subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital
stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options;
the capital stock of the Company conforms in all material respects to the description thereof contained in the Prospectus; and all the
outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been
duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors&#8217;
qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest,
restriction on voting or transfer or any other claim of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) <U>No Restrictions
on Subsidiaries</U>. Except as described in the Prospectus, no subsidiary of the Company is currently prohibited, directly or indirectly,
under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any
other distribution on such subsidiary&#8217;s capital stock, from repaying to the Company any loans or advances to such subsidiary from
the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) <U>No Conflicts</U>.
The execution, delivery and performance of this Agreement by the Company, the issuance and sale of the Shares and the consummation of
the other transactions contemplated by this Agreement will not (i) violate any provision of the Second Amended and Restated Certificate
of Incorporation or Seconded Amended and Restated Bylaws of the Company, in each case, as currently in effect, (ii) conflict with or result
in a violation of or default (with or without notice or lapse of time, or both) under, result in the creation or imposition of any lien,
charge or encumbrance upon or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control
right or to a loss of a benefit under any agreement or instrument, credit facility, indenture, deed of trust, mortgage, lease, license,
judgment, order, statute, law, ordinance, rule or regulations, applicable to the Company or any of its subsidiaries or their respective
properties or assets, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or any of its subsidiaries is subject (including federal and state securities
laws and regulations) and the rules and regulations of the Exchange, or by which any property or asset of the Company or any of its subsidiaries
is bound or affected, except, in the case of clauses (ii) and (iii), as would not, individually or in the aggregate, be reasonably expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) <U>No Consents
Required</U>. Except for the registration of the Shares under the Securities Act and applicable state securities laws, and such consents,
approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority
(&#8220;<B><I>FINRA</I></B>&#8221;) and the Exchange in connection with the sale of the Shares under this Agreement or any Terms Agreement
and the listing of the Shares on the Exchange, no consent, approval, authorization or order of, or filing, qualification or registration
(each an &#8220;<B><I>Authorization</I></B>&#8221;) with, any court, governmental or regulatory agency or body, foreign or domestic, which
has not been made, obtained or taken and is not in full force and effect, is required for the execution, delivery and performance of this
Agreement or any Terms Agreement by the Company, the issuance and sale of the Shares or the consummation of the transactions contemplated
hereby and thereby; and no event has occurred that allows or results in, or after notice or lapse of time or both would allow or result
in, revocation, suspension, termination or invalidation of any such Authorization or any other impairment of the rights of the holder
or maker of any such Authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) <U>Independent
Auditors</U>. M&amp;K CPA&#8217;s, PLLC, who have certified certain financial statements of the Company and its subsidiaries included
in the Prospectus is an independent registered public accounting firm with respect to the Company and its subsidiaries within the meaning
of Article 2-01 of Regulation S-X and the rules of the Public Company Accounting Oversight Board (United States) (the &#8220;<B><I>PCAOB</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o) <U>Financial
Statements</U>. The financial statements, together with the related notes, included in the Prospectus fairly present in all material respects
the financial position and the results of operations and changes in financial position of the Company and its consolidated subsidiaries
at the respective dates or for the respective periods therein specified. Such statements and related notes have been prepared in accordance
with the generally accepted accounting principles in the United States (&#8220;<B><I>GAAP</I></B>&#8221;) applied on a consistent basis
throughout the periods involved except as may be set forth in the related notes included in the Prospectus. The financial statements,
together with the related notes, included in the Prospectus comply in all material respects with Regulation S-X. No other financial statements
or supporting schedules or exhibits are required by Regulation S-X to be described or included in the Prospectus. There is no pro forma
or as adjusted financial information which is required to be included in the Prospectus, in accordance with Regulation S-X, which has
not been included or incorporated as so required. All information contained in the Prospectus regarding &#8220;non-GAAP financial measures&#8221;
(as defined in Regulation G) complies with Regulation G and Item 10 of Regulation S-K, to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p) <U>eXtensible
Business Reporting Language</U>. The interactive data in eXtensible Business Reporting Language included in the Prospectus fairly presents
the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines
applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q) <U>No Material
Adverse Change</U>. Neither the Company nor any of its subsidiaries has sustained, since the date of the latest audited financial statements
included in the Prospectus, (i) any material loss or interference with its business from fire, explosion, flood or other calamity, whether
or not covered by insurance, or from any labor dispute or action, order or decree of any court or governmental or regulatory authority,
other than as set forth or contemplated in the Prospectus; (ii) any change in the capital stock (other than the issuance of Common Shares
upon exercise of stock options and warrants described as outstanding in the Prospectus or any award under any Exempt Plan and the grant
of options and other awards under any Exempt Plan) or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution
of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock; or (iii) any material adverse
changes, or any development involving a prospective material adverse change, in or affecting the business, properties, assets, general
affairs, management, financial position, prospects, stockholders&#8217; equity or results of operations of the Company and its subsidiaries
taken as a whole, other than as set forth or contemplated in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r) <U>Legal Proceedings</U>.
Except as set forth in the Prospectus, there is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry
pending or, to the Company&#8217;s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the
aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments
or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that
have had or would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any subsidiary, nor to the knowledge
of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been, the subject of any
action involving a claim of violation of or liability under federal or state securities laws relating to the Company or such subsidiary
or a claim of breach of fiduciary duty relating to the Company or such subsidiary, which, individually or in the aggregate, has or would
reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s) <U>No Violation
or Default</U>. Neither the Company nor any of its subsidiaries is (i) in violation of its Second Amended and Restated Certificate of
Incorporation or Second Amended and Restated Bylaws (or analogous governing instrument, as applicable), (ii) in default in any respect,
and no event has occurred which, with notice or lapse of time or both, would constitute such a default, in the due performance or observance
of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument
to which it is a party or by which it is bound or to which any of its property or assets is subject or (iii) in violation in any respect
of any law, ordinance, governmental rule, regulation or court order, decree or judgment to which it or its property or assets may be subject,
except, in the case of clauses (ii) and (iii) above, for any such violation or default that could not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect.  </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(t) <U>Licenses or
Permits</U>. Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of violations with respect
to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality, except
for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect.
The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, &#8220;<B><I>Governmental
Authorizations</I></B>&#8221;) from such federal, state or local government or governmental agency, department or body that are currently
necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess
currently such Governmental Authorizations has not had and is not reasonably expected, individually or in the aggregate, to have a Material
Adverse Effect. Neither the Company nor any subsidiary has received any written (or, to the Company&#8217;s knowledge, oral) notice regarding
any revocation or material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject
of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(u) <U>Investment
Company Act</U>. Neither the Company nor any of its subsidiaries is or, after giving effect to the offer and sale of the Shares and the
application of the proceeds thereof as described in the Prospectus, will be required to register as an &#8220;investment company&#8221;
or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940,
as amended, and the rules and regulations of the Commission thereunder (the &#8220;<B><I>Investment Company Act</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v)  <U>No Stabilization</U>.
Neither the Company nor, to the Company&#8217;s knowledge, any of its officers, directors or affiliates has taken or will take, directly
or indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which caused or
resulted in, or which might in the future reasonably be expected to cause or result in, stabilization or manipulation of the price of
any security of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(w)  <U>Intellectual
Property</U>. The Company and its subsidiaries own, or have rights to use, all material inventions, patent applications, patents, trademarks,
trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary of
confidential information, systems or procedures) and other intellectual property as described in the Prospectus necessary for, or used
in the conduct of their respective businesses (including as described in the Prospectus) (collectively, &#8220;<B><I>Intellectual Property</I></B>&#8221;),
except where any failure to own or have rights to use such Intellectual Property has not had, and would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. The Intellectual Property owned by the Company and its subsidiaries has not
been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company&#8217;s knowledge:
(i) there are no third parties who claim any ownership rights to any Intellectual Property owned by the Company and its subsidiaries;
and (ii) there is no infringement by third parties of any Intellectual Property owned by the Company and its subsidiaries, except, in
each case of (i) and (ii), which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material
Adverse Effect. No action, suit, or other proceeding is pending, or, to the Company&#8217;s knowledge, is threatened in writing: (A) challenging
the Company&#8217;s or its subsidiaries&#8217; rights in or to any Intellectual Property owned by the Company and its subsidiaries; (B)
challenging the validity, enforceability or scope of any Intellectual Property; or (C) alleging that the Company or any of its subsidiaries
infringes, misappropriates, or otherwise violates any patent, trademark, trade name, service name, copyright, trade secret or other intellectual
property rights of others, except, in each case of (A) through (C), which, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect. Except, in each case, which, individually or in the aggregate, have not had
and would not reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries have complied with the terms
of each agreement pursuant to which Intellectual Property has been licensed to the Company or any of its subsidiaries, and to the Company&#8217;s
knowledge all such agreements are in full force and effect. The Company and its subsidiaries have taken all commercially reasonable steps
to protect and maintain the Intellectual Property owned by the Company and its subsidiaries, except where any failure to so protect or
maintain, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(x) <U>Regulatory
Permits</U>. The Company and its subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the Prospectus, except
where the failure to possess such permits would not, individually or in the aggregate, reasonably be expected to result in a Material
Adverse Effect (&#8220;<B><I>Material Permits</I></B>&#8221;), and neither the Company nor any subsidiary has received any notice of proceedings
relating to the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(y) <U>IT Systems</U>.
The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &#8220;<B><I>IT Systems</I></B>&#8221;) are adequate for, and operate and perform
in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently
conducted, and, to the Company&#8217;s actual knowledge, are free and clear of all material Trojan horses, time bombs, malware and other
malicious code. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative
controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential
or regulated data (&#8220;<B><I>Confidential Data</I></B>&#8221;) used or maintained in connection with their businesses and Personal
Data (defined below), and the integrity, availability continuous operation, redundancy and security of all IT Systems. &#8220;Personal
Data&#8221; means the following data used in connection with the Company&#8217;s and its subsidiaries&#8217; businesses and in their possession
or control: (i) a natural person&#8217;s name, street address, telephone number, e-mail address, photograph, social security number or
other tax identification number, driver&#8217;s license number, passport number, credit card number or bank information; (ii) information
that identifies or may reasonably be used to identify an individual; (iii) any information that would qualify as &#8220;protected health
information&#8221; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology
for Economic and Clinical Health Act (collectively, &#8220;<B><I>HIPAA</I></B>&#8221;); and (iv) any information that would qualify as
&#8220;personal data,&#8221; &#8220;personal information&#8221; (or similar term) under the Privacy Laws. To the Company&#8217;s knowledge,
there have been no breaches, outages or unauthorized uses of or accesses to the Company&#8217;s IT Systems, Confidential Data, or Personal
Data that would require notification under Privacy Laws (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(z) <U>Compliance
with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable
state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure,
transfer, disposal, or any other processing (collectively &#8220;<B><I>Process</I></B>&#8221; or &#8220;<B><I>Processing</I></B>&#8221;)
of Personal Data, including without limitation HIPAA, all other local, state and federal laws relating to the regulation of the Company
or its subsidiaries, and the regulations promulgated pursuant to such statutes and any state (collectively, the &#8220;<B><I>Privacy Laws</I></B>&#8221;).
To ensure material compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate
steps necessary to ensure compliance in all material respects with their policies and procedures relating to data privacy and security,
and the Processing of Personal Data and Confidential Data (the &#8220;<B><I>Privacy Statements</I></B>&#8221;). The Company and its subsidiaries
have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, at all times
since inception provided accurate notice of their Privacy Statements then in effect to its customers, employees, third party vendors and
representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete,
or in material violation of any Privacy Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(aa) <U>Compliance
with Health Care Laws</U>. The Company and its subsidiaries are in compliance in all material respects with all Health Care Laws to the
extent applicable to the current business of the Company and its subsidiaries or any of their respective activities. For purposes of this
Agreement, &#8220;<B><I>Health Care Laws</I></B>&#8221; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et
seq.) and the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable
federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C.
Section 1320a-7b(b)); (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section
17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation
Act of 2010; (vii) licensure, quality, safety and accreditation requirements under applicable federal, state, local or regulatory bodies;
(viii) all other local, state, federal, national, supranational, relating to the regulation of the Company or its subsidiaries, and (ix)
the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its
subsidiaries has received written or, to the Company&#8217;s knowledge, oral notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging
that any product operation or activity is in material violation of any Health Care Laws nor, to the Company&#8217;s knowledge, is any
such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its
subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected
or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements,
monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.
Additionally, neither the Company nor any of its subsidiaries nor any of their respective employees, officers, directors, or, to the knowledge
of the Company, agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical
research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action
that would reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(bb) <U>Bank Holding
Company Act</U>. Neither the Company nor any of its subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as
amended (the &#8220;<B><I>BHCA</I></B>&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;<B><I>Federal
Reserve</I></B>&#8221;). Neither the Company nor any of its subsidiaries or Affiliates owns or controls, directly or indirectly, five
percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(cc) <U>Title to
Real and Personal Property</U>. Each of the Company and its subsidiaries has good and marketable title to all personal property owned
by it that is material to the business of the Company and its subsidiaries taken as a whole, free and clear of all liens, encumbrances
and defects except such as are disclosed in the Prospectus, do not materially and adversely affect the value of such property and do not
materially and adversely interfere with the use made and proposed to be made of such property by the Company or its subsidiaries, as the
case may be. Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable
leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company or its subsidiaries, as the case may be. The Company does not own any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(dd)  <U>Compliance
with ERISA; No Labor Dispute</U>. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has
been established and administered in accordance with its terms and in compliance with the applicable provisions of Employee Retirement
Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#8220;<B><I>ERISA</I></B>&#8221;),
the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<B><I>Code</I></B>&#8221;), and other applicable laws, rules and regulations.
The Company and its subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding
employment, except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse
Effect. There is no labor dispute, strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the
Company, threatened which, individually or in the aggregate, would reasonably be expected to interfere with the business activities of
the Company, except where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a
Material Adverse Effect. For purposes of this Agreement, &#8220;<B><I>Benefit Plan</I></B>&#8221; or &#8220;<B><I>Benefit Plans</I></B>&#8221;
means employee benefit plans as defined in Section 3(3) of ERISA, and all other employee benefit practices or arrangements, including,
without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for disability,
retirement benefits, deferred compensation, bonus pay, incentive pay, stock options or other stock-based compensation, hospitalization
insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by the Company or to which the Company
or any of its subsidiaries is obligated to contribute for employees or former employees of the Company and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ee) <U>Environmental
Laws and Hazardous Materials</U>. The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal,
state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances
or wastes, pollutants or contaminants (&#8220;<B><I>Environmental Laws</I></B>&#8221;), (ii) have received all permits and other Governmental
Authorizations required under applicable Environmental Laws to conduct their business and (iii) are in compliance with all terms and conditions
of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits,
licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company nor any of its subsidiaries has received
since January 1, 2024, any written notice or other communication (in writing or otherwise), whether from a governmental authority or other
person, that alleges that the Company or any subsidiary is not in compliance with any Environmental Law and, to the knowledge of the Company,
there are no circumstances that may prevent or interfere with the Company&#8217;s or any subsidiary&#8217;s compliance in any material
respects with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material
Adverse Effect. To the knowledge of the Company: (i) no current or (during the time a prior property was leased or controlled by the Company)
prior property leased or controlled by the Company or any subsidiary has received since January 1, 2024, any written notice or other communication
relating to property owned or leased at any time by the Company, whether from a governmental authority, or other person, that alleges
that such current or prior owner or the Company or any subsidiary is not in compliance with or violated any Environmental Law relating
to such property and (ii) the Company has no material liability under any Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ff)  <U>Taxes</U>.
Each of the Company and 180 SPV Treasury Vehicle I, LLC have filed all federal, state and foreign income Tax Returns and other Tax Returns
required to have been filed under applicable law (or extensions have been duly obtained) and has paid all Taxes required to have been
paid by it, except for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with
United States federal tax returns has been made against the Company without subsequently being paid, settled or withdrawn. The charges,
accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined
are adequate to meet any assessments or reassessments for additional income tax for any years not finally determined, except to the extent
of any inadequacy that would not result in a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any
material amounts of Taxes of the Company and its subsidiaries are presently in progress or have been asserted or proposed in writing without
subsequently being paid, settled or withdrawn. There are no liens on any of the assets of the Company. At all times since inception, the
Company has been and continues to be classified as a corporation for U.S. federal income tax purposes. Neither the Company nor any of
its subsidiaries has been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during
the period specified in Section 897(c)(1)(A)(ii) of the Code. For purposes of this Agreement, (i) &#8220;<B><I>Tax</I></B>&#8221; or &#8220;<B><I>Taxes</I></B>&#8221;
means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including
any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto), whether or not imposed on the
Company or its subsidiaries (if any) including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross
receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding,
employment, social security, workers&#8217; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation,
premium, windfall profits, transfer and gains taxes and customs duties; and (ii) &#8220;<B><I>Tax Returns</I></B>&#8221; means returns,
reports, information statements and other documentation (including any additional or supporting material) filed or maintained, or required
to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any
amended returns required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(gg)  <U>Insurance</U>.
The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably
situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased)
and tangible assets, and each of such insurance policies is in full force and effect and the Company is in compliance in all material
respects with the terms of such insurance policies. Other than customary end-of-policy notifications from insurance carriers, since January
1, 2024, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation
of any material insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under
any insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(hh) <U>Accounting
Controls; Disclosure Controls</U>. The Company maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f)
and 15d-15(f) of the Exchange Act) that is designed to comply with the requirements of the Exchange Act applicable to the Company and
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that the Company maintains
records that in reasonable detail accurately and fairly reflect the Company&#8217;s transactions and dispositions of assets, (ii) that
transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and
expenditures are made only in accordance with authorizations of management and the Board and (iv) regarding prevention or timely detection
of the unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s
financial statements. Except as disclosed in the Prospectus, the Company has not identified any material weaknesses in the design or operation
of the Company&#8217;s internal control over financial reporting. The Company&#8217;s &#8220;disclosure controls and procedures&#8221;
(as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to provide reasonable assurance that all information (both
financial and non-financial) required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information
is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) <U>No Registration
Rights</U>. No person or entity has the right to require registration of Common Shares or other securities of the Company or any of its
subsidiaries because of the filing or effectiveness of the Registration Statement or otherwise, except for persons and entities who have
expressly waived such right in writing or who have been given timely and proper written notice and have failed to exercise such right
within the time or times required under the terms and conditions of such right. Except as described in the Prospectus, there are no persons
with registration rights or similar rights to have any securities registered by the Company or any of its subsidiaries under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(jj)  <U>No Broker&#8217;s
Fees</U>. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other
than this Agreement or any Terms Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or Clear
Street for a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of the Shares or any transaction
contemplated by this Agreement or by any Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(kk)  <U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ll)  <U>Listing</U>.
Except as disclosed in the Prospectus, the Company is subject to and in compliance in all material respects with the reporting requirements
of Section 13 or Section 15(d) of the Exchange Act. The Common Shares are registered pursuant to Section 12(b) or Section 12(g) of the
Exchange Act and are listed on the Exchange, and the Company has taken no action designed to, or reasonably likely to have the effect
of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Exchange, nor has
the Company received any notification that the Commission or the Exchange is contemplating terminating such registration or listing. All
of the Shares that have been or may be sold under this Agreement or any Terms Agreement have been approved for listing on the Exchange,
subject only to official notice of issuance (if applicable); the Company has taken all necessary actions to ensure that, upon and at all
times after the Exchange shall have approved the Shares for listing, it will be in compliance with all applicable corporate governance
requirements set forth in the Exchange&#8217;s listing rules that are then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(mm) <U>Sarbanes-Oxley
Act</U>. The Company is, and since January 1, 2024 has been, in compliance in all material respects with all applicable requirements of
the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(nn)  <U>Anti-Bribery
and Anti-Money Laundering</U>. Neither the Company nor any of its subsidiaries, nor to the knowledge of the Company, any agent or other
person acting on behalf of the Company or any such subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign
or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, or (iii)
otherwise violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. The operations of the
Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable
rules and regulations thereunder (collectively, the &#8220;<B><I>Money Laundering Laws</I></B>&#8221;), and no proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to
the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(oo)  <U>Statistical
and Market Data</U>. The statistical and market related data included in the Prospectus are based on or derived from sources that the
Company believes to be reliable and accurate, and such data agree with the sources from which they are derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(pp)  <U>Sanctions</U>.
Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate
or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of
any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of
the U.S. Department of the Treasury (&#8220;<B><I>OFAC</I></B>&#8221;) or the U.S. Department of State and including, without limitation,
the designation as a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221;), the United Nations Security Council,
the European Union, His Majesty&#8217;s Treasury or other relevant sanctions authority (collectively, &#8220;<B><I>Sanctions</I></B>&#8221;),
nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of
Sanctions, including, without limitation, the so-called Donetsk People&#8217;s Republic, so-called Luhansk People&#8217;s Republic, any
other Covered Region of Ukraine identified pursuant to Executive Order 14065, the Crimea region and non-government controlled areas of
the Zaporizhzhia and Kherson Regions of Ukraine, Cuba, Iran, North Korea and Syria (each, a &#8220;<B><I>Sanctioned Country</I></B>&#8221;);
and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities
of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund
or facilitate any activities of or business in any Sanctioned Country, or (iii) in any other manner that will result in a violation by
any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings
or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with
any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(qq) <U>Crypto Assets
and Related Third-Party Arrangements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)   The
Company owns, directly or indirectly, and has good and valid title to all material Crypto Assets reflected in its financial statements
or otherwise held in connection with its business, free and clear of all liens, encumbrances, pledges, and security interests, other than
as disclosed in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)   The
Company holds Crypto Assets either (i) in digital wallets or cold storage under its sole control, or (ii) through custodial arrangements
with Coinbase Global, Inc. (the &#8220;<B><I>Custodian</I></B>&#8221;), which is subject to a written agreement with the Company that
includes provisions addressing fiduciary duties (as applicable), asset segregation, loss and theft protections, incident reporting, and
compliance with applicable law. To the Company&#8217;s knowledge, the Custodian is duly authorized or registered, as required, under applicable
U.S. federal or state law to perform digital asset custody services and complies in all material respects with applicable regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)   The
Company has authorized Electric Treasury Edge, LLC (the &#8220;<B><I>Asset Manager</I></B>&#8221;) to manage or invest its Crypto Assets
pursuant to an Asset Management Agreement dated as of August 4, 2025 (the &#8220;<B><I>Asset Management Agreement</I></B>&#8221;). The
Asset Management Agreement (x) does not transfer beneficial ownership of the Crypto Assets, (y) preserves the Company&#8217;s right to
withdraw or liquidate such assets upon reasonable notice, and (z) requires periodic performance and risk reporting. The Company conducts
diligence on such service providers, monitors their activity, and maintains the ability to audit transactions and balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)   The
Company has implemented internal controls, security protocols, and oversight procedures designed to safeguard its Crypto Assets, manage
operational and custodial risks, and ensure accurate recordkeeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)   The
Company is in compliance with all applicable laws, rules, and regulations (including those administered by the SEC, Commodities Futures
Trading Commission, FinCEN, OFAC, and applicable state regulators) governing the holding, custody, transfer, and management of Crypto
Assets. To the Company&#8217;s knowledge, no part of its Crypto Assets portfolio has been used in violation of applicable Money Laundering
Laws, counter-terrorist financing, or economic Sanctions laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)   The
Company has not received any written notice from any governmental or regulatory authority asserting that its Crypto Asset activities,
or those of any of the Custodian or the Asset Manager, are or have been in violation of law. The Company accounts for its Crypto Assets
and related arrangements in accordance with GAAP, including current accounting guidance, and its disclosures reflect the nature of custodial
relationships, risk of loss, and any arrangements that affect legal control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">For purposes of
this Agreement, &#8220;<B><I>Crypto Assets</I></B>&#8221; means digital assets that are issued or transferred using distributed ledger
or blockchain technology, including but not limited to cryptocurrencies (e.g., Bitcoin, Ethereum), stablecoins, and other fungible or
non-fungible tokens held or used by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(rr)  <U>No Associated
Persons; FINRA Matters</U>. Neither the Company nor any of its affiliates (within the meaning of FINRA Rule 5121(f)(1)) directly or indirectly
controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article I, Section 1(ee)
of the By-laws of FINRA) of, any member firm of FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ss) <U>No Acquisitions
or Dispositions</U>. Except as are described in the Prospectus, there are no contracts, letters of intent, term sheets, agreement, arrangements
or understandings with respect to the direct or indirect acquisition or disposition by the Company of material interests in real or personal
property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(tt) <U>Other At
The Market Sales Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other &#8220;at the
market&#8221; offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any certificate signed by
an officer of the Company and delivered to Clear Street or to counsel for Clear Street pursuant to or in connection with this Agreement
or any Terms Agreement shall be deemed to be a representation and warranty by the Company to Clear Street as to the matters set forth
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges that
Clear Street and, for purposes of the opinions to be delivered pursuant to Section 7, counsel to the Company and counsel to Clear Street,
will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. <I>Covenants
of the Company.</I> The Company covenants and agrees with Clear Street that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Registration
Statement Amendments</U>. After the date of this Agreement and during any period in which a Prospectus relating to any Shares is required
to be delivered by Clear Street under the Securities Act or the Rules and Regulations (including in circumstances where such requirement
may be satisfied pursuant to Rule&nbsp;172 of the Rules and Regulations) (a &#8220;<B><I>Delivery Period</I></B>&#8221;), (i)&nbsp;the
Company will notify Clear Street promptly of the time when any subsequent amendment to the Registration Statement, other than documents
incorporated by reference, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus
has been filed, (ii) the Company will prepare and file with the Commission, promptly upon Clear Street&#8217;s request, any amendments
or supplements to the Registration Statement or Prospectus that, in Clear Street&#8217;s reasonable opinion, may be necessary or advisable
in connection with the distribution of the Shares by Clear Street (<I>provided, however</I>, that the failure of Clear Street to make
such request shall not relieve the Company of any obligation or liability hereunder, or affect Clear Street&#8217;s right to rely on the
representations and warranties made by the Company in this Agreement or any Terms Agreement); (iii) the Company will not file any amendment
or supplement to the Registration Statement or the Prospectus, other than documents incorporated by reference, relating to the Shares
or a security convertible into the Shares unless a copy thereof has been submitted to Clear Street within a reasonable period of time
before the filing and Clear Street has not reasonably objected thereto (<I>provided, however</I>, that (x) the failure of Clear Street
to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect Clear Street&#8217;s right to
rely on the representations and warranties made by the Company in this Agreement or any Terms Agreement and (y) the only remedy that Clear
Street shall have with respect to the failure by the Company to submit such filing to Clear Street for review (other than Clear Street&#8217;s
rights under Section 9 hereof), shall be to cease making sales under this Agreement until such amendment or supplement is filed); (iv)
the Company will cause each amendment or supplement to the Prospectus, other than documents incorporated by reference, to be filed with
the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act, and (v) prior to the termination
of this Agreement, the Company will notify Clear Street if at any time the Registration Statement shall no longer be effective as a result
of the passage of time pursuant to Rule 415 under the Securities Act or otherwise. Prior to the initial sale of any Shares, the Company
shall file a final Prospectus Supplement pursuant to Rule 424(b) relating to the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Notice of
Commission Stop Orders</U>. The Company will advise Clear Street, promptly after it receives notice or obtains knowledge thereof, of the
issuance by the Commission of any stop order or of any order preventing or suspending the use of the Prospectus, of the suspension of
the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such
purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for
additional information. In the event of the issuance of any stop order or of any order preventing or suspending the use of the Prospectus
or suspending any such qualification, the Company shall use its best efforts to obtain the withdrawal of such order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Delivery of
Prospectus; Subsequent Changes</U>. During any Delivery Period, the Company will comply with all requirements imposed upon it by the Securities
Act and the Rules and Regulations, as from time to time in force, and to file on or before their respective due dates all reports and
any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c),
14, 15(d) or any other provision of the Exchange Act or the Exchange Act Rules and Regulations. If during such period any event occurs
as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during
such period it is necessary to amend or supplement the Registration Statement or the Prospectus to comply with the Securities Act or the
Rules and Regulations, the Company will promptly notify Clear Street to suspend the offering of Shares during such period and the Company
will promptly amend or supplement the Registration Statement or the Prospectus (at the expense of the Company) so as to correct such statement
or omission or effect such compliance; <I>provided however,</I> that the Company may delay any such amendment or supplement if (i) there
is no outstanding Placement Notice, (ii) Clear Street is not otherwise required to deliver the Prospectus under the Securities Act and
the Rules and Regulations, and (iii) the Company believes, in the reasonable judgment of the Company, it is in the best interests of the
Company not to file such amendment or supplement or effect such compliance. Until such time as the Company shall have corrected such misstatement
or omission or effected such compliance, the Company shall not issue a Placement Notice to Clear Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Blue Sky Compliance</U>.
The Company shall promptly, from time to time, take such actions as Clear Street may reasonably request to qualify the Shares for offering
and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as Clear Street may reasonably designate and
to continue such qualifications in effect, and to comply with such laws, for so long as required to permit the offer and sale of Shares
in such jurisdictions; <I>provided, however</I>, that the Company and its subsidiaries shall not be obligated to (i) qualify as foreign
corporations in any jurisdiction in which they are not so qualified, (ii) file a general consent to service of process in any jurisdiction,
or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Earnings Statement</U>.
The Company will make generally available to its stockholders as soon as practicable, but in any event not later than 15 months after
the end of the Company&#8217;s current fiscal quarter, an earnings statement of the Company and its subsidiaries (which need not be audited)
complying with Section 11(a) of the Securities Act (including, at the option of the Company, Rule 158).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Expenses</U>.
The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, in accordance with
the provisions of Section 11, will pay the following expenses all incident to the performance of its obligations hereunder, including,
but not limited to, expenses relating to (i) the preparation, printing and filing of the Registration Statement (and each amendment and
supplement thereto) and the Prospectus (and each amendment and supplement thereto), (ii) the preparation, issuance and delivery of the
Shares, (iii) the qualification of the Shares under securities laws in accordance with the provisions of Section 7(d), including filing
fees and associated legal expenses of Clear Street&#8217;s outside counsel, (iv) the printing and delivery to Clear Street of copies of
the Prospectus and any amendments or supplements thereto, (v) the fees and expenses incurred in connection with the listing or qualification
of the Shares for trading on the Exchange, (vi) the filing fees and expenses, if any, of the Commission, (vii) the filing fees and associated
legal expenses of Clear Street&#8217;s outside counsel for filings with the FINRA Corporate Financing Department, such legal expense reimbursement
not to exceed $10,000 and, (viii) the reasonable fees and disbursements of Clear Street&#8217;s counsel (A) in an amount not to exceed
$75,000 arising out of executing this Agreement or any Terms Agreement and the satisfaction of the Company&#8217;s covenants with respect
to the First Delivery Date and (B) in an amount not to exceed $10,000 in connection with each Bring-Down Date (as defined below) on which
the Company is required to provide a Bring-Down Certificate (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Use of Proceeds</U>.
To apply the Net Proceeds as set forth in the Prospectus under the heading &#8220;Use of Proceeds.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) <U>Clear Market</U>.
Without the prior written consent of Clear Street, the Company will not, directly or indirectly, offer to sell, sell, contract to sell,
grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement or any Terms
Agreement) or securities convertible into or exchangeable or exercisable for Common Shares, warrants or any rights to purchase or acquire
Common Shares during the period beginning on the third Trading Day immediately prior to the date on which any Placement Notice is delivered
to Clear Street hereunder and ending on the second Trading Day immediately following the final Settlement Date with respect to Shares
sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Shares covered
by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other &#8220;at the market
offering&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose
of any Common Shares (other than the Shares offered pursuant to this Agreement or any Terms Agreement) or securities convertible into
or exchangeable or exercisable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the later of the
termination of this Agreement or any Terms Agreement and the 30th day immediately following the final Settlement Date with respect to
Shares sold pursuant to such Placement Notice; <I>provided, however</I>, that such restrictions will not be required in connection with
the Company&#8217;s issuance, grant or sale of (i)&nbsp;Common Shares, options to purchase Common Shares or other securities under an
Exempt Plan, (ii) Common Shares issuable upon the exercise of options or vesting of other securities, pursuant to any Exempt Plan, (iii)
Common Shares issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or outstanding, and
disclosed in the Prospectus, or (iv)&nbsp;Common Shares or securities convertible into or exchangeable for Common Shares as consideration
for mergers, acquisitions, other business combinations or strategic alliances occurring after the date of this Agreement, which are not
issued for capital raising purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) <U>Change of
Circumstances</U>. The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement Notice or
sell Shares hereunder or pursuant to a Terms Agreement, advise Clear Street promptly after it shall have received notice or obtained knowledge
thereof, of any information or fact that would alter or affect in any material respect any opinion, certificate, letter or other document
provided to Clear Street pursuant to this Agreement or any Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) <U>Due Diligence
Cooperation</U>. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted by Clear
Street or its agents in connection with the transactions contemplated hereby or by any Terms Agreement, including, without limitation,
providing information and making available documents and senior corporate officers, during regular business hours and at the Company&#8217;s
principal offices, as Clear Street may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) <U>Required Filings
Relating to Placement of Shares</U>. The Company agrees that on such dates as the Securities Act or the Rules and Regulations shall require,
the Company will (i)&nbsp;file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) of the Rules
and Regulation, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales
were effected as may be required by the rules or regulations of such exchange or market. The Company shall disclose in its Quarterly Reports
on Form 10-Q and in its Annual Report on Form 10-K, the number of Shares sold under this Agreement and any Terms Agreement, and the gross
proceeds and Net Proceeds to the Company from the sale of the Shares and the compensation paid by the Company with respect to sales of
the Shares pursuant to this Agreement and any Terms Agreement during the relevant quarter or, in the case of an Annual Report on Form
10-K, during the fiscal year covered by such Annual Report and the fourth quarter of such fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) <U>Bring-Down
Dates; Bring-Down Certificate</U>. On or prior to the First Delivery Date and each time (i) the Company files the Prospectus relating
to the Shares or amends or supplements the Registration Statement or the Prospectus relating to the Shares (other than a prospectus supplement
filed in accordance with Section 7(k)) by means of a post-effective amendment, sticker, or supplement but not by means of incorporation
of document(s) by reference into the Registration Statement or the Prospectus relating to the Shares; (ii) the Company files an Annual
Report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material amendment
to the previously filed Annual Report on Form 10-K); (iii) the Company files its Quarterly Reports on Form 10-Q under the Exchange Act
(including any Form 10-Q/A containing amended financial information or a material amendment to the previously filed Quarterly Report on
Form 10-Q); or (iv) the Company files a current report on Form 8-K containing amended financial information (other than an earnings release)
under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv), a &#8220;<B><I>Bring-Down
Date</I></B>&#8221;); the Company shall furnish Clear Street with a certificate, in the form attached hereto as <U>Exhibit 7(l)</U> (a
&#8220;<B><I>Bring-Down Certificate</I></B>&#8221;), within one Trading Day of any Bring-Down Date, if requested by Clear Street. The
requirement to provide a certificate under this Section 7(l) shall be waived for any Bring-Down Date occurring at a time at which no Placement
Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder
(which for such calendar quarter shall be considered a Bring-Down Date) and the next occurring Bring-Down Date; <I>provided, however</I>,
that such waiver shall not apply for any Bring-Down Date on which the Company files its Annual Report on Form 10-K. Notwithstanding the
foregoing, if the Company subsequently decides to sell Shares in an Agency Transaction following a Bring-Down Date when the Company relied
on such waiver and did not provide Clear Street with a certificate under this Section 7(l), then before the Company delivers the Placement
Notice or Clear Street sells any Shares pursuant to such Agency Transaction, the Company shall provide Clear Street with a Bring-Down
Certificate, dated the date of the Placement Notice. With respect to any Principal Transaction, a Bring-Down Certificate shall be delivered
on the Principal Settlement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) <U>Legal Opinion</U>.
On or prior to the First Delivery Date and within one Trading Day of each Bring-Down Date with respect to which the Company is obligated
to deliver a Bring-Down Certificate for which no waiver is applicable, the Company shall cause to be furnished to Clear Street written
opinions of The Loev Law Firm, PC and Gunderson Dettmer Stough Villeneuve Frankling &amp; Hachigian, LLP (&#8220;<B><I>Company Counsels</I></B>&#8221;)
and negative assurance letter from The Loev Law Firm, PC, or other counsel satisfactory to Clear Street, in form and substance satisfactory
to Clear Street and its counsel, dated the date that the opinion is required to be delivered; <I>provided, however</I>, that in lieu of
such opinions for subsequent Bring-Down Dates, counsel may furnish Clear Street with a letter to the effect that Clear Street may rely
on a prior opinion delivered under this Section 7(m) to the same extent as if it were dated the date of such letter (except that statements
in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Bring-Down
Date). With respect to any Principal Transaction, the Company shall cause to be furnished to Clear Street written opinions of Company
Counsels, or other counsel satisfactory to Clear Street, in form and substance satisfactory to Clear Street and its counsel, dated the
Principal Settlement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) <U>Comfort Letter</U>.
On or prior to the First Delivery Date and within one Trading Day of each Bring-Down Date with respect to which the Company is obligated
to deliver a Bring-Down Certificate for which no waiver is applicable, the Company shall cause its independent accountants to furnish
Clear Street a letter (a &#8220;<B><I>Comfort Letter</I></B>&#8221; and the first such letter, the &#8220;<B><I>Initial Comfort Letter</I></B>&#8221;),
dated the date the Comfort Letter is delivered, in form and substance satisfactory to Clear Street, (i) confirming that they are an independent
registered public accounting firm within the meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the conclusions
and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&#8217; &#8220;comfort
letters&#8221; to Clear Street in connection with registered public offerings, and (iii) updating the Initial Comfort Letter with any
information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate
to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter. With respect to any Principal
Transaction, the Company shall cause its independent accountants to furnish Clear Street Comfort Letters, dated the date of the Terms
Agreement and the Principal Settlement Date, in form and substance satisfactory to Clear Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o) <U>Chief Accounting
Officer&#8217;s Certificate</U>. On or prior to the First Delivery Date and within one Trading Day of each Bring-Down Date with respect
to which the Company is obligated to deliver a Bring-Down Certificate for which no waiver is applicable, if requested by Clear Street,
the Company shall have delivered to Clear Street a certificate executed by the Chief Accounting Officer of the Company, providing &#8220;management
comfort&#8221; with respect to certain financial data included in the Prospectus, dated as of such date, in form and substance satisfactory
to Clear Street (a &#8220;<B><I>CAO Certificate</I></B>&#8221;). With respect to any Principal Transaction, if requested by Clear Street,
the Company shall have delivered to Clear Street a CAO Certificate, dated the date of the Terms Agreement and the Principal Settlement
Date, in form and substance satisfactory to Clear Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p) <U>Secretary&#8217;s
Certificate</U>. On or prior to the First Delivery Date and within one Trading Day of each Bring-Down Date with respect to which the Company
is obligated to deliver a Bring-Down Certificate for which no waiver is applicable, the Company shall have delivered to Clear Street a
certificate executed by the Secretary of the Company, dated as of such date, in form and substance satisfactory to Clear Street. With
respect to any Principal Transaction, the Company shall have delivered to Clear Street a certificate executed by the Secretary of the
Company, dated the date of the Principal Settlement Date, in form and substance satisfactory to Clear Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q) <U>Market Activities</U>.
The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or would reasonably
be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of the Shares or (ii) sell, bid for, or purchase the Common Shares to be issued and sold pursuant to this Agreement or any Terms Agreement,
or pay anyone any compensation for soliciting purchases of the Shares other than Clear Street; <I>provided, however</I>, that the Company
may bid for and purchase Common Shares in accordance with Rule 10b-18 of the Exchange Act Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r) <U>Insurance</U>.
The Company and its subsidiaries shall maintain, or cause to be maintained, insurance in such amounts and covering such risks as is reasonable
and customary for the business for which they are engaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s) <U>Compliance
with Laws</U>. The Company and each of its subsidiaries shall use commercially reasonable efforts to maintain, or cause to be maintained,
all material Governmental Permits in order to conduct their businesses as described in the Prospectus, and the Company and each of its
subsidiaries shall conduct their businesses, or cause their businesses to be conducted, in substantial compliance with such Governmental
Permits and with applicable environmental laws, except where the failure to maintain or be in compliance with such Governmental Permits
and laws could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(t) <U>Investment
Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor its subsidiaries
will be or become, at any time prior to the termination of this Agreement, an &#8220;investment company,&#8221; as such term is defined
in the Investment Company Act, assuming no change in the Commission&#8217;s current interpretation as to entities that are not considered
an investment company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(u) <U>Securities
Act and Exchange Act</U>. The Company will use its best efforts to comply with all requirements imposed upon it by the Securities Act,
the Rules and Regulations, the Exchange Act, and the Exchange Act Rules and Regulations as from time to time in force, so far as necessary
to permit the continuance of sales of, or dealings in, the Shares as contemplated by the provisions hereof and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) <U>No Offer to
Sell</U>. Other than a Permitted Free Writing Prospectus, neither Clear Street nor the Company (including its agents and representatives,
other than Clear Street in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as
defined in Rule 405 of the Rules and Regulations), required to be filed with the Commission, that constitutes an offer to sell or solicitation
of an offer to buy Shares hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(w) <U>Sarbanes-Oxley</U>.
The Company and its subsidiaries will use their best efforts to comply with all effective applicable provisions of Sarbanes-Oxley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(x) <U>Affirmation</U>.
Each Placement Notice delivered by the Company to Clear Street and each execution and delivery by the Company of a Terms Agreement shall
be deemed to be (i) an affirmation that the representations, warranties and agreements of the Company herein contained and contained in
any certificate delivered to Clear Street pursuant hereto are true and correct at the time of delivery of such Placement Notice or the
date of such Terms Agreement, as the case may be, and (ii) an undertaking that such representations, warranties and agreements will be
true and correct on any applicable Time of Sale and Settlement Date, as though made at and as of each such time (it being understood that
such representations, warranties and agreements shall relate to the Registration Statement and the Prospectus as amended and supplemented
to the time of such Placement Notice acceptance or Terms Agreement execution, as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(y) <U>Renewal</U>.
If immediately prior to the third anniversary (the &#8220;<B><I>Renewal Deadline</I></B>&#8221;) of the initial effective date of the
Registration Statement, the aggregate gross sales price of Shares sold by the Company is less than the Maximum Amount and this Agreement
has not expired or been terminated, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible
to do so, a new shelf registration statement relating to the Shares, in form and substance satisfactory to Clear Street, and, if not automatically
effective, will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline.
The Company will take all other reasonable actions necessary or appropriate to permit the issuance and sale of the Shares to continue
as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall include
such new shelf registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <I>Conditions
to Clear Street&#8217;s Obligations.</I> The obligations of Clear Street hereunder with respect to a Placement Notice or any Terms Agreement
will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due
performance by the Company of its obligations hereunder and thereunder, to the completion by Clear Street of a due diligence review satisfactory
to Clear Street in its reasonable judgment, and to the continuing satisfaction (or waiver by Clear Street in its sole discretion) of the
following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Registration
Statement Effective</U>. The Registration Statement shall be effective and shall be available for (i) all sales of Shares issued pursuant
to all prior Placement Notices or any Terms Agreement and (ii) the sale of all Shares contemplated to be issued pursuant to any Placement
Notice or Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>No Material
Notices</U>. None of the following events shall have occurred and be continuing: (i) receipt by the Company or any of its subsidiaries
of any request for additional information from the Commission or any other federal or state governmental authority during the period of
effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration
Statement or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental authority of any stop
order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt
by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Shares
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event
that makes any material statement made in the Registration Statement or the Prospectus or any material document incorporated or deemed
to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration
Statement, related Prospectus or such documents so that, in the case of the Registration Statement, it will not contain any materially
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>No Misstatement
or Material Omission</U>. Clear Street shall not have advised the Company that the Registration Statement or Prospectus, or any amendment
or supplement thereto, contains an untrue statement of fact that in Clear Street&#8217;s reasonable opinion is material, or omits to state
a fact that in Clear Street&#8217;s opinion is material and is required to be stated therein or is necessary to make the statements therein
(in the case of the Prospectus, in the light of the circumstances then existing) not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>No Material
Adverse Effect</U>. Except as disclosed in the Prospectus, there shall not have been any material adverse change, on a consolidated basis,
in the authorized capital stock of the Company or any Material Adverse Effect or any development that would reasonably be expected to
result in a Material Adverse Effect, or any downgrading in or withdrawal of the rating assigned to any of the Company&#8217;s securities
(other than asset backed securities) by any rating organization or a public announcement by any rating organization that it has under
surveillance or review its rating of any of the Company&#8217;s securities (other than asset backed securities), the effect of which,
in the case of any such action by a rating organization described above, in the reasonable judgment of Clear Street (without relieving
the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed
with the offering of the Shares on the terms and in the manner contemplated in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Company Counsels
Legal Opinions</U>. Clear Street shall have received the opinions of Company Counsels and negative assurance letter required to be delivered
pursuant to Section 7(m) on or before the date on which such delivery of such opinion is required pursuant to Section 7(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Clear Street
Counsel Legal Opinion</U>. Clear Street shall have received from Paul Hastings LLP, counsel for Clear Street, such opinion or opinions
and negative assurance letter, on or before the date on which the delivery of the Company Counsels legal opinions is required pursuant
to Section 7(m), with respect to such matters as Clear Street may reasonably require, and the Company shall have furnished to such counsel
such documents as they request for enabling them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Comfort Letters</U>.
Clear Street shall have received the Comfort Letters required to be delivered pursuant to Section 7(o) on or before the date on which
such delivery of such Comfort Letters are required pursuant to Section 7(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) <U>CAO Certificate</U>.
Clear Street shall have received the CAO Certificate required to be delivered pursuant to Section 7(o) on or before the date on which
delivery of such certificate is required pursuant to Section 7(o).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) <U>Bring-Down
Certificate</U>. Clear Street shall have received the Bring-Down Certificate required to be delivered pursuant to Section 7(l) on or before
the date on which delivery of such certificate is required pursuant to Section 7(l).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) <U>Secretary&#8217;s
Certificate</U>. On or prior to the First Delivery Date and at each Principal Settlement Date, Clear Street shall have received a certificate,
executed by the Secretary of the Company, in form and substance satisfactory to Clear Street and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) <U>No Suspension</U>.
Trading in the Common Shares shall not have been suspended on the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) <U>Other Materials</U>.
On each date on which the Company is required to deliver a Bring-Down Certificate pursuant to <U>Section 7(l)</U>, in addition to each
of the deliverables otherwise required by Section 7, the Company shall have furnished to Clear Street such appropriate further information,
certificates and documents as Clear Street may have reasonably requested. All deliverables shall have been in compliance, and delivered
when required by, the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) <U>Securities
Act Filings Made</U>. All filings with the Commission required by Rule 424 of the Rules and Regulations to have been filed prior to the
issuance of any Shares hereunder or under any Terms Agreement shall have been made within the applicable time period prescribed for such
filing by Rule 424. The Company shall file a prospectus supplement in connection with any Principal Transaction within the applicable
time period prescribed for such filing by Rule 424.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) <U>Listing on
the Exchange</U>. Either (i) the Shares shall have been approved for listing on the Exchange, subject only to notice of issuance, or (ii)
the Company shall have filed an application for listing of the Shares on the Exchange, at, or prior to, the First Placement Notice Date
and the Exchange shall have reviewed such application and not provided any objections thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o) <U>No Termination
Event</U>. There shall not have occurred any event that would permit Clear Street to terminate this Agreement pursuant to Section 11(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9. <I>Indemnification
and Contribution.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Indemnification
of Clear Street by the Company</U>. The Company shall indemnify and hold harmless Clear Street, its affiliates, directors, officers, managers,
members, employees, representatives and agents and each person, if any, who controls Clear Street within the meaning of Section 15 of
the Securities Act or Section 20 of the Exchange Act (collectively the &#8220;<B><I>Clear Street Indemnified Parties</I></B>,&#8221; and
each a &#8220;<B><I>Clear Street Indemnified Party</I></B>&#8221;) against any loss, claim, damage, expense or liability whatsoever (or
any action, investigation or proceeding in respect thereof), joint or several, to which such Clear Street Indemnified Party may become
subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding
arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
the Prospectus (including any free writing prospectus), or in any amendment or supplement thereto or (ii) the omission or alleged omission
to state in any such document a material fact required to be stated therein or necessary to make the statements therein not misleading,
and shall reimburse each Clear Street Indemnified Party promptly upon demand for any legal fees or other expenses reasonably incurred
by that Clear Street Indemnified Party in connection with investigating, or preparing to defend, or defending against, or appearing as
a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action,
investigation or proceeding, as such fees and expenses are incurred; <I>provided, however</I>, that the Company shall not be liable in
any such case to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement
or alleged untrue statement in, or omission or alleged omission from any such document made in reliance upon and in conformity with written
information furnished to the Company by or on behalf of Clear Street specifically for use therein, it being understood and agreed that
the only such information furnished by or on behalf of Clear Street is its name (the &#8220;<B><I>Clear Street Information</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indemnity agreement in
this Section 9(a) is not exclusive and is in addition to each other liability which the Company might have, and shall not limit any rights
or remedies which may otherwise be available under this Agreement, at law or in equity to any Clear Street Indemnified Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Indemnification
of the Company by Clear Street</U>. Clear Street shall indemnify and hold harmless the Company and its directors, its officers who signed
the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act (collectively the &#8220;<B><I>Company Indemnified Parties</I></B>&#8221; and each a &#8220;<B><I>Company
Indemnified Party</I></B>&#8221;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding
in respect thereof), joint or several, to which such Company Indemnified Party may become subject, under the Securities Act or otherwise,
insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus (including any issuer
free writing prospectus), or in any amendment or supplement thereto, or (ii) the omission or alleged omission to state in any such document,
a material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only to the
extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity
with written information furnished to the Company by or on behalf of Clear Street specifically for use therein, which information the
parties hereto agree is limited to the Clear Street Information, and shall reimburse the Company Indemnified Parties for any legal or
other expenses reasonably incurred by such party in connection with investigating or preparing to defend or defending against or appearing
as third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees and
expenses are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indemnity agreement in
this Section 9(b) is not exclusive and is in addition to each other liability which Clear Street might have, and shall not limit any rights
or remedies which may otherwise be available under this Agreement, at law or in equity to any Company Indemnified Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Indemnification
Procedure</U>. Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any action, the indemnified
party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section 9, notify such indemnifying
party in writing of the commencement of that action; <I>provided, however</I>, that the failure to notify the indemnifying party shall
not relieve it from any liability which it may have under this Section 9 except to the extent it has been materially prejudiced by such
failure (through the forfeiture of substantive rights or defenses); and, <I>provided, further,</I> that the failure to notify an indemnifying
party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section 9. If any such
action shall be brought against an indemnified party, and it shall notify the indemnifying party thereof, the indemnifying party shall
be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to
assume the defense of such action with counsel satisfactory to the indemnified party (which counsel shall not, except with the written
consent of the indemnified party, be counsel to the indemnifying party). After notice from the indemnifying party to the indemnified party
of its election to assume the defense of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified
party under Section 9 for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense of
such action other than reasonable costs of investigation; <I>provided, however</I>, that any indemnified party shall have the right to
employ separate counsel in any such action and to participate in the defense of such action but the fees and expenses of such counsel
(other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i) the employment thereof has
been specifically authorized in writing by the Company in the case of a claim for indemnification under Section 9(a) or Clear Street in
the case of a claim for indemnification under Section 9(b), (ii) such indemnified party shall have been advised by its counsel that there
may be one or more legal defenses available to it which are different from or additional to those available to the indemnifying party,
or (iii) the indemnifying party has failed to assume the defense of such action and employ counsel reasonably satisfactory to the indemnified
party within a reasonable period of time after notice of the commencement of the action or the indemnifying party does not diligently
defend the action after assumption of the defense, in which case, if such indemnified party notifies the indemnifying party in writing
that it elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to
assume the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense, to continue to defend)
such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently
incurred by such indemnified party in connection with the defense of such action; <I>provided, however</I>, that the indemnifying party
shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising
out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of
attorneys at any time for all such indemnified parties (in addition to any local counsel), which firm shall be designated in writing by
Clear Street if the indemnified parties under this Section 9 consist of any Clear Street Indemnified Party or by the Company if the indemnified
parties under this Section&nbsp;9 consist of any Company Indemnified Parties. Subject to this Section 9(c), the amount payable by an indemnifying
party under Section 9 shall include, but not be limited to, (i) reasonable legal fees and expenses of counsel to the indemnified party
and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third party witness in respect
of, or otherwise incurred in connection with, any action, investigation, proceeding or claim, and (ii) all amounts paid in settlement
of any of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise
or consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification
or contribution could be sought under this Section 9 (whether or not the indemnified parties are actual or potential parties thereto),
unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party in form and substance reasonably
satisfactory to such indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as
to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the
following sentence, no indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever that
is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written
consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the
indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such
settlement or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the
indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement
of the nature contemplated herein effected without its written consent if (i) such settlement is entered into more than 45 days after
receipt by such indemnifying party of the request for reimbursement, (ii) such indemnifying party shall have received notice of the terms
of such settlement at least 30 days prior to such settlement being entered into, and (iii)&nbsp;such indemnifying party shall not have
reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Contribution</U>.
If the indemnification provided for in this Section 9 is unavailable or insufficient to hold harmless an indemnified party under Section
9(a) or 9(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable
or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation
or proceeding in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the relative benefits received
by the Company on the one hand and Clear Street on the other from the offering of the Shares, or (ii) if the allocation provided by clause
(i) of this Section 9(d) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) of this Section 9(d) but also the relative fault of the Company, on the one hand, and Clear Street, on the other,
with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage, expense or liability (or
any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and Clear Street, on the other, with respect to such offering shall be deemed to be in the same
proportion as the total Net Proceeds from the sale of the Shares received by the Company bear to the total compensation received by Clear
Street from the sale of the Shares on behalf of the Company. The relative fault of the Company, on the one hand, and Clear Street, on
the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or Clear
Street, on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent
such untrue statement, omission, act or failure to act; <I>provided</I> that the parties hereto agree that the written information furnished
to the Company by or on behalf of Clear Street for use in the Registration Statement, the Prospectus (including any free writing prospectus),
or in any amendment or supplement thereto, consists solely of the Clear Street Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Contribution
Procedure</U>. The Company and Clear Street agree that it would not be just and equitable if contributions pursuant to Section 9(d) above
were to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations
referred to Section 9(d) above. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability,
action, investigation or proceeding referred to in Section 9(d) above shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend
or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim,
damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section 9, Clear Street shall
not be required to contribute any amount in excess of the amount by which total compensation received by Clear Street from the sale of
Shares on behalf of the Company exceeds the amount of any damages which Clear Street has otherwise paid or become liable to pay by reason
of any untrue or alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10. <I>Representations
and Agreements to Survive Delivery.</I> The indemnity and contribution agreements contained in Section 9 of this Agreement and all representations
and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless
of (i) any investigation made by or on behalf of Clear Street, any controlling persons, or the Company (or any of their respective officers,
directors or controlling persons), (ii) delivery and acceptance of the Shares and payment therefor, or (iii) any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11. <I>Termination.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Clear Street
shall have the right by giving notice as hereinafter specified at any time to terminate this Agreement if (i) the Company shall have suffered
any Material Adverse Effect, or any development that could reasonably be expected to result in a Material Adverse Effect, that, in the
judgment of Clear Street, may materially impair the ability of Clear Street to sell the Shares hereunder, (ii) the Company shall have
failed, refused or been unable to perform any agreement on its part to be performed hereunder, (iii)&nbsp;any other condition of Clear
Street&#8217;s obligations hereunder is not fulfilled as and when required, or (iv) any suspension or limitation of trading in the Shares
or in securities generally on the Exchange shall have occurred. Any such termination shall be without liability of any party to any other
party except that the provisions of Section 7(f) (Expenses), Section 9 (Indemnification and Contribution), Section 10 (Representations
and Agreements to Survive Delivery) and Section 17 (Governing Law, Jurisdiction, Waiver of Jury Trial) hereof shall remain in full force
and effect notwithstanding such termination. If Clear Street elects to terminate this Agreement as provided in this Section 11(a), Clear
Street shall provide the required notice as specified in Section 12 (Notices).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) In the case of
any purchase by Clear Street pursuant to a Terms Agreement, the obligations of Clear Street pursuant to such Terms Agreement shall be
subject to termination by Clear Street at any time prior to or on the Principal Settlement Date if since the time of execution of the
Terms Agreement or the respective dates as of which information is given in the Registration Statement or the Prospectus, (A) there has
been any Material Adverse Effect or material change in the senior management of the Company, whether or not arising in the ordinary course
of business&#894; (B) there has occurred any outbreak or escalation of hostilities or other national or international calamity or crisis
or change in economic, political or other conditions, the effect of which on the United States or international financial markets is such
as to make it, in Clear Street&#8217;s judgment, impracticable to market the Shares or enforce contracts for the sale of the Shares&#894;
(C) trading in any securities of the Company has been suspended by the Commission or by the Exchange, or if trading generally on the Nasdaq
has been suspended (including an automatic halt in trading pursuant to market-decline triggers, other than those in which solely program
trading is temporarily halted), or limitations on prices for trading (other than limitations on hours or numbers of days of trading) have
been fixed, or maximum ranges for prices for securities have been required, by such exchange or FINRA or by order of the Commission or
any other governmental authority&#894; (D) any federal, state, local or foreign statute, regulation, rule or order of any court or other
governmental authority has been enacted, published, decreed or otherwise promulgated which, in the opinion of Clear Street, would reasonably
be expected to result in a Material Adverse Effect&#894; or (E) any action has been taken by any federal, state, local or foreign government
or agency in respect of its monetary or fiscal affairs which, in the opinion of Clear Street, would reasonably be expected to have a material
adverse effect on the securities markets in the United States. If Clear Street elects to terminate its obligations pursuant to this Section
11(b), the Company shall be notified promptly in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The Company shall
have the right, by giving 10 days&#8217; notice as hereinafter specified to terminate this Agreement in its sole discretion <FONT STYLE="font-weight: normal">at
any time after the date of this Agreement</FONT>. Any such termination shall be without liability of any party to any other party except
that the provisions of Section 7(f) (Expenses), Section 9 (Indemnification and Contribution), Section 10 (Representations and Agreements
to Survive Delivery) and Section 17 (Governing Law, Jurisdiction, Waiver of Jury Trial) hereof shall remain in full force and effect notwithstanding
such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Clear Street
shall have the right, by giving 10 days&#8217; notice as hereinafter specified to terminate this Agreement in its sole discretion <FONT STYLE="font-weight: normal">at
any time after the date of this Agreement</FONT>. Any such termination shall be without liability of any party to any other party except
that the provisions of Section 7(f) (Expenses), Section 9 (Indemnification and Contribution), Section 10 (Representations and Agreements
to Survive Delivery) and Section 17 (Governing Law, Jurisdiction, Waiver of Jury Trial) hereof shall remain in full force and effect notwithstanding
such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) Unless earlier
terminated pursuant to this Section 11, this Agreement shall automatically terminate upon the issuance and sale of all of the Shares through
Clear Street on the terms and subject to the conditions set forth herein; <I>provided</I> that the provisions of Section 7(f) (Expenses),
Section 9 (Indemnification and Contribution), Section 10 (Representations and Agreements to Survive Delivery) and Section 17 (Governing
Law, Jurisdiction, Waiver of Jury Trial) hereof shall remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;This Agreement shall
remain in full force and effect unless terminated pursuant to Sections 11(a), (c), or (d) above or otherwise by mutual agreement of the
parties; <I>provided, however</I>, that any such termination by mutual agreement shall in all cases be deemed to provide that Section
7(f) (Expenses), Section 9 (Indemnification and Contribution), Section 10 (Representations and Agreements to Survive Delivery) and Section
17 (Governing Law, Jurisdiction, Waiver of Jury Trial) shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) Any termination
of this Agreement shall be effective on the date specified in such notice of termination; <I>provided, however</I>, that such termination
shall not be effective until the close of business on the date of receipt of such notice by Clear Street or the Company, as the case may
be. If such termination shall occur prior to the Settlement Date for any sale of Shares, such Shares shall settle in accordance with the
provisions of this Agreement. Upon termination of this Agreement, the Company shall not be required to pay to Clear Street any discount
or commission with respect to any Shares not otherwise sold by Clear Street under this Agreement; <I>provided, however,</I> that the Company
shall remain obligated to reimburse Clear Street&#8217;s expenses pursuant to Section 7(f) (Expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12. <I>Notices</I>.
All statements, requests, notices and agreements hereunder shall be in writing, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;if to Clear Street,
shall be delivered or sent by mail or email to Clear Street LLC, Attention: General Counsel, 4 World Trade Center, New York, New York
10006, email: bfriedman@clearstreet.io; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;if to the Company
shall be delivered or sent by mail or email to Blair Jordan, and Eric Van Lent, emails: bjordan@180lifesciences.com, and eric.van.lent@180lifesciences.com,
with copies to (which shall not constitute notice to): David M. Loev and Keith J. Scherer, emails: dloev@loevlaw.com and kscherer@gunder.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any such statements, requests,
notices or agreements shall take effect at the time of receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13. <I>Successors
and Assigns.</I> This Agreement and any Terms Agreement shall inure to the benefit of and be binding upon Clear Street, the Company and
their respective successors and assigns and the persons referred to in <U>Section 9</U> hereof. Nothing expressed or mentioned in this
Agreement or any Terms Agreement is intended or shall be construed to give any person, other than the persons mentioned in the preceding
sentence, any legal or equitable right, remedy or claim under or in respect of this Agreement or any such Terms Agreement, or any provisions
herein or therein contained, this Agreement or any such Terms Agreement and all conditions and provisions hereof or thereof being intended
to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations,
warranties, covenants, agreements and indemnities of the Company contained in this Agreement or such Terms Agreement shall also be for
the benefit of the Clear Street Indemnified Parties, and the indemnities of Clear Street shall be for the benefit of the Company Indemnified
Parties. Neither party may assign its rights or obligations under this Agreement or any Terms Agreement without the prior written consent
of the other party; <I>provided</I>, <I>however</I>, that Clear Street may assign its rights and obligations hereunder to an affiliate
of Clear Street without obtaining the Company&#8217;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14. <I>Adjustments
for Share Splits.</I> The parties acknowledge and agree that all share-related numbers contained in this Agreement or any Terms Agreement
shall be adjusted to take into account any share split, share dividend or similar event effected with respect to the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15. <I>Entire
Agreement; Construction; Amendment.</I> This Agreement (including any Placement Notices issued pursuant hereto), together with any Terms
Agreements, constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement or any Terms Agreement,
the masculine, feminine and neuter genders and the singular and the plural include one another. The section headings in this Agreement
and any Terms Agreement are for the convenience of the parties only and will not affect the construction or interpretation of this Agreement
or any such Terms Agreement. This Agreement and any Terms Agreement may be amended or modified, and the observance of any term of this
Agreement and any Terms Agreement may be waived, only by a writing signed by the Company and Clear Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16. <I>Partial
Unenforceability</I>. The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement or any Terms
Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision hereof. If any section,
paragraph, clause or provision of this Agreement or any Terms Agreement is for any reason determined to be invalid or unenforceable, there
shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17. <I>Governing
Law, Jurisdiction, Waiver of Jury Trial.</I> This Agreement and any Terms Agreement shall be governed by and construed in accordance with
the laws of the State of New York, including without limitation Section 5-1401 of the New York General Obligations. The Company irrevocably
(a) submits to the exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York for the
purpose of any suit, action or other proceeding arising out of this Agreement or the transactions contemplated by this Agreement or by
any Terms Agreement, the Registration Statement, or the Prospectus, (b) agrees that all claims in respect of any such suit, action or
proceeding may be heard and determined by any such court, (c) waives to the fullest extent permitted by applicable law, any immunity from
the jurisdiction of any such court or from any legal process, (d) agrees not to commence any such suit, action or proceeding other than
in such courts, and (e) waives, to the fullest extent permitted by applicable law, any claim that any such suit, action or proceeding
is brought in an inconvenient forum. <B>Each of the parties to this Agreement hereby waives any right to trial by jury in any suit or
proceeding arising out of or relating to this Agreement or any Terms Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18. <I>Absence
of Fiduciary Relationship.</I> The Company acknowledges and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Clear Street
has been retained solely to act as an arm&#8217;s length contractual counterparty to the Company in connection with the sale of the Shares
contemplated hereby and by any Terms Agreement and that no fiduciary, advisory or agency relationship between the Company and Clear Street
has been created in respect of any of the transactions contemplated by this Agreement or any Terms Agreement, irrespective of whether
Clear Street has advised or is advising the Company on other matters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) the Company is
capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by
this Agreement or any Terms Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) the Company has
been advised that Clear Street and its affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and that Clear Street has no obligation to disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) the Company waives,
to the fullest extent permitted by law, any claims it may have against Clear Street, for breach of fiduciary duty or alleged breach of
fiduciary duty and agrees that Clear Street shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary
claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders, partners, employees
or creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19. <I>Research
Analyst Independence.</I> The Company acknowledges that Clear Street&#8217;s research analysts and research department are required to
be independent from its investment banking division and are subject to certain regulations and internal policies, and that Clear Street&#8217;s
research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the
Company and/or its securities that differ from the views of its investment banking division. The Company hereby waives and releases, to
the fullest extent permitted by law, any claims that the Company may have against Clear Street with respect to any conflict of interest
that may arise from the fact that the views expressed by its independent research analysts and research department may be different from
or inconsistent with the views or advice communicated to the Company by Clear Street&#8217;s investment banking division. The Company
acknowledges that Clear Street is a full service securities firm and as such from time to time, subject to applicable securities laws,
may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20. <I>Counterparts.</I>
This Agreement and any Terms Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Delivery of an executed Agreement or any Terms Agreement by one party
to the other may be made by facsimile or other electronic transmission (including pdf or any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21. <I>Definition
of Certain Terms</I>. For purposes of this Agreement, (a) &#8220;<B><I>affiliate</I></B>&#8221; has the meaning set forth in Rule 405
of the Rules and Regulations, (b) &#8220;<B><I>subsidiary</I></B>&#8221; has the meaning set forth in Rule&nbsp;405 of the Rules and Regulations;
(c) &#8220;<B><I>BHC Act Affiliate</I></B>&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted
in accordance with, 12 U.S.C. &sect; 1841(k), (d) &#8220;<B><I>Covered Entity</I></B>&#8221; means any of the following: (i) a &#8220;covered
entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;252.82(b); (ii) a &#8220;covered bank&#8221;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;47.3(b); or (iii) a &#8220;covered FSI&#8221; as
that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;382.2(b), (e) &#8220;<B><I>Default Right</I></B>&#8221;
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as
applicable, and (f) &#8220;<B><I>U.S. Special Resolution Regime</I></B>&#8221; means each of (i) the Federal Deposit Insurance Act and
the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22. <I>Recognition
of the U.S. Special Resolution Regimes.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) In the event
that Clear Street is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from Clear
Street of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer
would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by
the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) In the event
that Clear Street is a Covered Entity and Clear Street or a BHC Act Affiliate of Clear Street becomes subject to a proceeding under a
U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against Clear Street are permitted to be exercised
to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed
by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Remainder of Page Intentionally Blank]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Company and Clear Street, please so indicate in the space provided below for that purpose, whereupon
this letter shall constitute a binding agreement between the Company and Clear Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>CLEAR STREET LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">/s/ Ryan Gerety</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Name: </TD>
    <TD STYLE="text-align: left">Ryan Gerety</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Title: </TD>
    <TD STYLE="text-align: left">Managing Director</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>ACCEPTED as of the date</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>first-above written:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>180 LIFE SCIENCES CORP.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><I>/s/ Blair Jordan</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Name:&nbsp;</TD>
    <TD STYLE="text-align: left">Blair Jordan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>form of PLACEMENT
NOTICE</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: left; text-indent: 0in">From:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Cc:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">To:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Subject:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Clear Street At the Market Offering&#8212;Placement Notice</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Pursuant to the terms and subject
to the conditions contained in the Sales Agreement between 180 Life Sciences Corp. (the &#8220;<B><I>Company</I></B>&#8221;) and Clear
Street LLC (&#8220;<B><I>Clear Street</I></B>&#8221;) dated August 13, 2025 (the &#8220;<B><I>Agreement</I></B>&#8221;), I hereby request
on behalf of the Company that Clear Street sell up to [        ]
shares of the Company&#8217;s Common Shares (as defined in the Agreement) at a minimum market price of $[ ] per share. Sales should begin
on the date of this Notice and shall continue until [DATE] [all shares are sold].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>SCHEDULE 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Notice Parties</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Company</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-align: justify">Blair Jordan</TD>
    <TD STYLE="width: 79%; text-align: justify">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Eric R. Van Lent</TD>
    <TD STYLE="text-align: justify">Chief Accounting Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-underline-style: double"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clear Street</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-align: justify">Ryan Gerety</TD>
    <TD STYLE="width: 79%; text-align: justify">Managing Director &#8211; Chief Operating Officer</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">atmtrading@clearstreet.io</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>SCHEDULE 2(b)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>180
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>[_________________]
SHARES<U><BR>
<BR>
<BR>
terms AGREEMENT<BR>
&nbsp;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">____, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clear Street LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4 World Trade Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies &amp; Gentlemen:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">180 Life Sciences Corp., a Delaware corporation
(the &#8220;<B><U>Company</U></B>&#8221;), proposes, subject to the terms and conditions stated herein and in the Sales Agreement, dated
August 13, 2025 (the &#8220;<B><U>Sales Agreement</U></B>&#8221;), between the Company and Clear Street LLC (&#8220;<B><U>Clear Street</U></B>&#8221;),
to issue and sell to Clear Street the securities specified in the Schedule hereto (the &#8220;<B><U>Purchased Securities</U></B>&#8221;).
Unless otherwise defined below, terms defined in the Sales Agreement shall have the same meanings when used herein.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the provisions of the Sales Agreement
not specifically related to the solicitation by Clear Street, as agent of the Company, of offers to purchase securities is incorporated
herein by reference in its entirety, and shall be deemed to be part of this Terms Agreement to the same extent as if such provisions had
been set forth in full herein. Each of the representations, warranties and agreements set forth therein shall be deemed to have been made
as of the date of this Terms Agreement and the Settlement Date set forth in the Schedule hereto.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An amendment to the Registration Statement or
a supplement to the Prospectus, as the case may be, relating to the Purchased Securities, in the form heretofore delivered to Clear Street,
is now proposed to be filed with the Commission.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions set forth
herein and in the Sales Agreement which are incorporated herein by reference, the Company agrees to issue and sell to Clear Street, and
Clear Street agrees to purchase from the Company, the Purchased Securities at the time and place and at the purchase price set forth in
the Schedule hereto.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of the Sales Agreement
or this Terms Agreement to the contrary, the Company consents to Clear Street trading in the Common Shares for Clear Street&#8217;s own
account and for the account of its clients at the same time as sales of the Purchased Securities occur pursuant to this Terms Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the foregoing is in accordance with your understanding,
please sign and return to us a counterpart hereof, whereupon this Terms Agreement, including those provisions of the Sales Agreement incorporated
herein by reference, shall constitute a binding agreement between Clear Street and the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">180 LIFE SCIENCES CORP.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Accepted and agreed as of </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">the date first above written: </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">CLEAR STREET LLC</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule to Terms Agreement&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Purchased Securities:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock, par value $0.0001 per share&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Shares of Purchased Securities:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[</B>&#9679;<B>]</B> Shares&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purchase Price Payable by Clear Street:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$<B>[</B>&#9679;<B>]</B> per Share&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Method of and Specified Funds for Payment of Purchase
Price:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[</B>By wire transfer to a bank account specified
by the Company in same day funds.<B>]</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Method of Delivery:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[</B>To Clear Street&#8217;s account, or the
account of Clear Street&#8217;s designee, at The Depository Trust Company via DWAC in return for payment of the purchase price.<B>]</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Settlement Date:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[</B>&#9679;<B>]</B>, 20<B>[</B>&#9679;<B>]</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Closing Location:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[</B>&#9679;<B>]&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Documents to be Delivered:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents referred to in the Sales
Agreement shall be delivered on the Settlement Date as a condition to the closing for the Purchased Securities (which documents shall
be dated on or as of the Settlement Date and shall be appropriately updated to cover any Permitted Free Writing Prospectuses and any amendments
or supplements to the Registration Statement, the Prospectus, any Permitted Free Writing Prospectuses and any documents incorporated by
reference therein):&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(1) the opinions of Company Counsels
and negative assurance letter of The Loev Law Firm, PC, referred to in Section 8(e);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(2) the opinion and negative assurance
letter of counsel to Clear Street referred to in Section 8(f);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(3) the Comfort Letters referred to
in Section 8(g);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(4) the CAO Certificate referred to
in Section 8(h);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(5) the Bring-Down Certificate referred
to in Section 8(i);&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(6) the Secretary&#8217;s Certificate
referred to in Section 8(j);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and (7) such other documents as Clear
Street shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Compensation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Clear Street shall be paid compensation up to 3%
of the gross proceeds from the sales of Shares pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>Exhibit 7(l) </U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>OFFICER&#8217;S CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[DATE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, the duly qualified and elected
Chief Executive Officer, of 180 Life Sciences Corp. (&#8220;<B><I>Company</I></B>&#8221;), a Delaware corporation, does hereby certify
in such capacity and on behalf of the Company, pursuant to Section 7(l) of the Sales Agreement dated August 13, 2025 (the &#8220;<B><I>Sales
Agreement</I></B>&#8221;) between the Company and Clear Street LLC, that, to the best of the knowledge of the undersigned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   The
representations and warranties of the Company in Section 6 of the Sales Agreement (i) to the extent such representations and warranties
are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct
on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations
and warranties that speak solely as of a specific date and which were true and correct as of such date, and (ii) to the extent such representations
and warranties are not subject to any qualifications or exceptions, are true and correct in all material respects as of the date hereof
as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof except for those
representations and warranties that speak solely as of a specific date and which were true and correct as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   The
Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement
at or prior to the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   The
Company does not possess any material non-public information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea025259601ex5-1_180life.htm
<DESCRIPTION>OPINION OF THE LOEV LAW FIRM, PC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 172px; width: 750px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">August 13, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">180 Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3000 El Camino Real, Bldg. 4, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Palo Alto, CA&nbsp;94306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>180 Life Sciences Corp.&nbsp;</B></FONT></TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Registration Statement on Form S-3 and Rule 424(b) Prospectus</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pc 0pt 0in; text-align: justify; text-indent: 0.25in">We have acted as special
counsel to 180 Life Sciences Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the Sales Agreement,
dated August 13, 2025 (the &ldquo;<U>Agreement</U>&rdquo;), by and among Clear Street LLC (the &ldquo;<U>Agent</U>&rdquo;), and the Company,
pursuant to which the Company may issue and sell shares of common stock, par value $0.0001 per share (the &ldquo;<U>Shares</U>&rdquo;).
The Shares have been offered for sale pursuant to a prospectus supplement dated August 13, 2025 (the &ldquo;<U>Prospectus Supplement</U>&rdquo;),
which was filed by the Company with the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo; or the &ldquo;<U>Commission</U>&rdquo;)
on August 13, 2025, pursuant to Rule 424(b) under the Securities Act and the base prospectus (such base prospectus, as amended and supplemented
by the Prospectus Supplement, the &ldquo;<U>Prospectus</U>&rdquo;) that form a part of the Company&rsquo;s registration statement on Form
S-3 (No. 333-288194), initially filed by the Company with the Commission on June 20, 2025, and declared effective by the Commission on
June 26, 2025 (the &ldquo;<U>Registration Statement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This opinion is being furnished
to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities
Act, in connection with the Registration Statement, and no opinion is expressed or may be implied herein as to any matter pertaining to
the contents of the Registration Statement, or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For purposes of rendering
this opinion, we have examined originals or copies (certified or otherwise identified to our satisfaction) of (i) the Registration Statement,
including the prospectus contained therein (the &ldquo;<U>Base Prospectus</U>&rdquo;); (ii) the Prospectus Supplement; (iii) the Second
Amended and Restated Certificate of Incorporation of the Company, as amended to date (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;);
(iv) the Second Amended and Restated Bylaws of the Company (the &ldquo;<U>Bylaws</U>&rdquo;); (v) the Agreement; and (vi) records of proceedings
of the Board of Directors, or committees thereof, and resolutions relating thereto (the &ldquo;<U>Resolutions</U>&rdquo;). We have also
examined such other certificates of public officials, such other certificates of officers of the Company and such other records, agreements,
documents and instruments as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. In rendering such
opinion, we have relied as to factual matters upon the representations, warranties and other statements made in the Agreement without
having independently verified such factual matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In delivering this opinion,
we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted
to us as originals, the conformity to originals of all documents submitted to us as certified, photostatic or conformed copies, the authenticity
of originals of all such latter documents, and the accuracy and completeness of all records, information and statements submitted to us
by officers and representatives of the Company. In making our examination of documents executed by parties other than the Company, we
have assumed that such parties had the power, corporate or other, to enter into and perform all obligations thereunder and have also assumed
the due authorization of all requisite action, corporate or other, and execution and delivery by such parties of such documents and the
validity and binding effect thereof with respect to such parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the foregoing
and the other matters set forth herein, it is our opinion that, as of the date hereof, the Shares have been duly authorized by all necessary
corporate action of the Company, and when the Shares are issued and paid for in accordance with the terms and conditions of the Agreement,
that upon issuance, the Shares will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, in connection with
our opinions expressed above, we have assumed that, (i) at or prior to the time of the delivery of any of the Shares, there will not have
occurred any change in the law or the facts affecting the validity of the Shares, (ii) at the time of the offer, issuance and sale of
any Shares, no stop order suspending the Registration Statement&rsquo;s effectiveness will have been issued and remain in effect, (iii)
no future amendments will be made to the Company&rsquo;s Certificate of Incorporation that would be in conflict with or inconsistent with
the Company&rsquo;s right and ability to issue the Shares, (iv) all purchasers of the Shares will timely pay in full to the Company all
amounts they have agreed to pay to purchase such Shares, as approved by the Board of Directors of the Company or a duly authorized committee
thereof, (v) that the purchase price of any Shares will not be less than the par value thereof, (vi) that the specific sale of the Shares
will be duly authorized by the Board of Directors of the Company, a duly authorized committee thereof or a person or body pursuant to
an authorization granted in accordance with Section 152 of the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;),
and (vii) that that the sale and issuance of the Shares will not exceed (a) the authorized number of shares of Common Stock set forth
in the Certificate of Incorporation, and (b)&nbsp;the aggregate amount of Shares authorized for offer, sale, and issuance by the Resolutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In rendering the foregoing
opinion, we have also assumed that: (i) the Company will issue and deliver the Shares in the manner contemplated by the Registration Statement
and the Prospectus; and (ii) the Shares will be issued in compliance with applicable federal and state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The foregoing opinion is
limited solely to DGCL and the federal laws of the United States of America and the reported decisions interpreting such law. We express
no opinion herein as to any other laws, statutes, ordinances, rules, or regulations (and in particular, we express no opinion as to any
effect that such other laws, statutes, ordinances, rules, or regulations may have on the opinions expressed herein). No opinion is expressed
herein with respect to the qualification of the Shares under the securities or blue-sky laws of any state or any foreign jurisdiction.
This opinion is limited to the matters set forth herein, and no other opinion should be inferred beyond the matters expressly stated.
We have made such examination of Delaware law as we have deemed relevant for purposes of this opinion. We express no opinion as to any
county, municipal, city, town or village ordinance, rule, regulation or administrative decision. We express no opinion as to the enforceability
of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This opinion is for your
benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to
the applicable provisions of the Act. We consent to the use of this opinion as an exhibit to the Current Report on Form 8-K to be filed
by the Company and further consent to all references to us in the Prospectus Supplement under &ldquo;<U>Legal Matters</U>&rdquo;. In giving
such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the
rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 39%; text-align: justify"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><I>/s/ The Loev Law Firm, PC</I></FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">The Loev Law Firm, PC</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+N17AI9@  34T *@    @ ! $[  (
M   ,   !2H=I  0    !   !5IR=  $    8   "SNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M969I;&4N961G87(   60 P "    %    J20!  "    %    KB2D0 "
M S,P  "2D@ "     S,P  #J'  '   !#    9@     '.H    !
M
M
M
M
M
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M (5=H/\ S]Z[_P"#NZ_^.4 =E17&_P#"KM!_Y^]=_P#!W=?_ !RC_A5V@_\
M/WKO_@[NO_CE '945QO_  J[0?\ G[UW_P '=U_\<H_X5=H/_/WKO_@[NO\
MXY0!V5%<;_PJ[0?^?O7?_!W=?_'*/^%7:#_S]Z[_ .#NZ_\ CE '945QO_"K
MM!_Y^]=_\'=U_P#'*/\ A5V@_P#/WKO_ (.[K_XY0!V5%<;_ ,*NT'_G[UW_
M ,'=U_\ '*/^%7:#_P _>N_^#NZ_^.4 =E17&_\ "KM!_P"?O7?_  =W7_QR
MC_A5V@_\_>N_^#NZ_P#CE '945QO_"KM!_Y^]=_\'=U_\<H_X5=H/_/WKO\
MX.[K_P".4 =E17&_\*NT'_G[UW_P=W7_ ,<H_P"%7:#_ ,_>N_\ @[NO_CE
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MRC_A5V@_\_>N_P#@[NO_ (Y0!V5%<;_PJ[0?^?O7?_!W=?\ QRC_ (5=H/\
MS]Z[_P"#NZ_^.4 =E17&_P#"KM!_Y^]=_P#!W=?_ !RC_A5V@_\ /WKO_@[N
MO_CE '945QO_  J[0?\ G[UW_P '=U_\<H_X5=H/_/WKO_@[NO\ XY0!V5%<
M;_PJ[0?^?O7?_!W=?_'*/^%7:#_S]Z[_ .#NZ_\ CE '945QO_"KM!_Y^]=_
M\'=U_P#'*/\ A5V@_P#/WKO_ (.[K_XY0!V5%<;_ ,*NT'_G[UW_ ,'=U_\
M'*/^%7:#_P _>N_^#NZ_^.4 =E17&_\ "KM!_P"?O7?_  =W7_QRC_A5V@_\
M_>N_^#NZ_P#CE '945QO_"KM!_Y^]=_\'=U_\<H_X5=H/_/WKO\ X.[K_P".
M4 =E17&_\*NT'_G[UW_P=W7_ ,<H_P"%7:#_ ,_>N_\ @[NO_CE '945QO\
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M?^?O7?\ P=W7_P <H_X5=H/_ #]Z[_X.[K_XY0!V5%<;_P *NT'_ )^]=_\
M!W=?_'*/^%7:#_S]Z[_X.[K_ ..4 =E17&_\*NT'_G[UW_P=W7_QRC_A5V@_
M\_>N_P#@[NO_ (Y0!V5%<;_PJ[0?^?O7?_!W=?\ QRC_ (5=H/\ S]Z[_P"#
MNZ_^.4 =E17&_P#"KM!_Y^]=_P#!W=?_ !RC_A5V@_\ /WKO_@[NO_CE '94
M5QO_  J[0?\ G[UW_P '=U_\<H_X5=H/_/WKO_@[NO\ XY0!V5%<;_PJ[0?^
M?O7?_!W=?_'*/^%7:#_S]Z[_ .#NZ_\ CE '945QO_"KM!_Y^]=_\'=U_P#'
M*/\ A5V@_P#/WKO_ (.[K_XY0!V5%<;_ ,*NT'_G[UW_ ,'=U_\ '*/^%7:#
M_P _>N_^#NZ_^.4 =E17&_\ "KM!_P"?O7?_  =W7_QRC_A5V@_\_>N_^#NZ
M_P#CE '945QO_"KM!_Y^]=_\'=U_\<H_X5=H/_/WKO\ X.[K_P".4 =E17&_
M\*NT'_G[UW_P=W7_ ,<H_P"%7:#_ ,_>N_\ @[NO_CE '945QO\ PJ[0?^?O
M7?\ P=W7_P <H_X5=H/_ #]Z[_X.[K_XY0!V5%<;_P *NT'_ )^]=_\ !W=?
M_'*/^%7:#_S]Z[_X.[K_ ..4 =E17&_\*NT'_G[UW_P=W7_QRC_A5V@_\_>N
M_P#@[NO_ (Y0!V5%<;_PJ[0?^?O7?_!W=?\ QRC_ (5=H/\ S]Z[_P"#NZ_^
M.4 =D#FBJ6DZ5;Z+IL=C9M.\4>=K7$[S.<G/+.23^)HH NT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%&: "BD+A>IQ31*AZ,* 'T9K-U_6H- \.W^KW"/+%90-.Z1
M_>8*,X%<!;?'+1+KPK8ZQ%97;3Z@[16NFH TTT@.-H[8]^E 'J.117SWJ_Q+
M^,MQJ2G2?!4=I:E\",Q^<Q&?XG#8'Y5[1X=O=0O+1&U.#R92H+H#D*<<C\Z
M-RBBB@ HHHH ***3(H 6BF>:@."PS3P<]* "BBB@ HHHH **** "BBB@ HHH
MH ***,T %%-:5%^\P'UI0P89!S0 M%%% !1110 4444 %%%% !1110 449I-
MP'>@!:*3>OJ*3>OK0 ZBJ6J:QIVB:;)J&KWD-G:1??FF<*H_&FZ=K6GZM!'/
MIMU%<PRJ&CDB;*L#W!H OT444 %%%% !1110 4444 %%%% !129%(9%'4B@!
MU%-$B$X# T[- !11FFF15^\0* '44T.K="#3J "BBB@ HHHH **** "BBB@
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M\6R>$_A;>O:2F*\OR+2%@<$;OO$?\!!KC?@1X:6Q\+V)9,277^DRDCKG[O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M! M--MM1N%W75W&&RW_+.(G(4>F>OXUZ[XS:P\,>"M=UU;:)+J+3V4S!0';
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXCBU^]TT2:I"%$=P97^7;T^7.WCZ5UM% %6PL(K"'RXAQ6-XL\!>'?&PM?\
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M%;JH..G%'EIDG:,GJ<=:Y'_A"-6_Z'WQ%_Y+?_&:/^$(U;_H??$7_DM_\9H
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M:*-_O(I^HKDO^$(U;_H??$7_ )+?_&:/^$(U;_H??$7_ )+?_&: .N"*!@
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M/+3;C:,>F*Y'_A"-6_Z'WQ%_Y+?_ !FC_A"-6_Z'WQ%_Y+?_ !F@#KRJL,$
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MO$D@ D0-@Y&X9P:=L4=JY#_A"-6_Z'WQ%_Y+?_&:/^$(U;_H??$7_DM_\9H
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M:M_T/OB+_P EO_C- '7%%)R5!-+M&<@<UR'_  A&K?\ 0^^(O_);_P",T?\
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MN[33;/3S=:JL.S&2<1J"5)!)(/TH ],S15&\U"ST73Q-J-T(HUVH))3\SL>
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MC3RA@[$]>!@9H ]PS1FN5U+2_"_AWP>\5Y<MI6C*_F2.+R1-V1T+YW8/H#7
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M;.3Z"M+Q?K7B+PHWA*[DU!I[S4M3AL[VR55\EA)]X(,9&WL<]N: /3J*044
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M?2MOX5:C:Z!\.;;5]<:4ZAXAU)YK@1P.[^?*W"D $@  <G@"O5B >HS2  =
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M J:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\Y^-UO>7/@>T%O;S7-I'JEM)J$<*EF^SJV6.!UY"U)XW$?C[0K+P[H'^D6U_
M<127EPJ$1P6R,';)/\1P%"]>2>U>A4@ '0 ?2@#EM:\5:':Z/+"L#:M+L*1Z
M=# 9'E;& I4C ^IP!7C>J> /$/A[X/:1::A'(T;^(8[_ %"S@)D%G 2<(,=0
MIP3BOHT* <@#/KBEH \Z\8Z6WQ)N]+T*Q<_\(_#,EYJ5R 0LH7[D">I)Y/H!
MZUC>$5_X1WXR>.KS7TD@>Z\DV#&,D30*O"QX')& ,"O7@ !@# H(!QD9QTH
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M]*ZWX6:A8:_H-SXATNTNM.BU";:VGS_=MWC&QM@]SDGIS]* .ZHHHH ****
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MTX@O()6AFC'H'4@X]JGB\,Z7'?PWTL#75Y;J5AN;J1I7C!Z[2Q./PK7R*,T
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M)9FDV*!@ %B3CVK(/PY\-?\ "27&N16<T%]=-ON#!=21I,WJR*P4GZBNJHH
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M$\V0OC<N?0XQ].* .>\+>,_$LOA'P;HUS=&;7O$3RS&\G0%H+-26\PC@%]@
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MC' ).35VBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5:5!<6TC.6BC) 8B3."5'.,8..M7HO$^B2W,MO%J=N\T,1F=%?)"#JWN/<4
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M44@%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@!,4N*** #%)BE
MHH 3%%+10 F*,4M% "8HI:* $Q[48I:* $Q[48I:* $Q12T4 )BC%+10 8I
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MV^E>=6WPOUV?P_I-MOMM)O=)M+G%U%+ODNKJ9&#,S #";F)QR>GI7L&!2X%
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M4$4(80QI&&8LVU<9)ZDT 2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atnf-20250813.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aw5s7xRiXgen8uLYXBcWaKOqcPtwJF9CYkhuWp2bemaPyEoMRf/XCC+uqQGUSAB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180lifesciences.com/20250813" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20250813">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250813_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250813_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20250813_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>atnf-20250813_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="atnf-20250813.xsd#Cover" roleURI="http://180lifesciences.com/role/Cover" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250813.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250813.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>atnf-20250813_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20250813.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20250813.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>atnf-20250813_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="atnf-20250813.xsd#Cover" roleURI="http://180lifesciences.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250813.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20250813.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 13,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2875 South Ocean<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palm Beach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0252596-8k_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20250813.xsd</File>
    <File>atnf-20250813_def.xml</File>
    <File>atnf-20250813_lab.xml</File>
    <File>atnf-20250813_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0252596-8k_180life.htm">ea0252596-8k_180life.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0252596-8k_180life.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20250813",
   "dts": {
    "schema": {
     "local": [
      "atnf-20250813.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20250813_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20250813_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20250813_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0252596-8k_180life.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 26
   },
   "report": {
    "R1": {
     "role": "http://180lifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0252596-8k_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0252596-8k_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "auth_ref": []
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20250813",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20250813",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001213900-25-075972-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-075972-xbrl.zip
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MX"W3PN[1 BU*@(-:.-UX'-VH(QW/DI?O'<@9MH#Y(EZ0<*?[C:=K1.G'4.H
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M @2)(%2/\@G2%8T87[/*XP[G;",ZP.=S-H=G*!U1;J'J584Z6JTA 0'6QR>
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M FV3#_;;_!OWP_UU WOD;U!+ P04    " "WJPU;\4R(& <<  #[D@  &
M &5A,#(U,C4Y-BTX:U\Q.#!L:69E+FAT;>T]:5?;R++?_2OZ>6;ND'.]2%X
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ME=H9/C8&W"8#ZO0,:XO@4"4-"<X0($5CU99OLNPY[?$P/1HPBB>SGCW$I[4
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MN;2:4YQ\;(#PHL&Q8*FVDW+8R'#A.3 ]U-)P;XQJ_&5R.!C?6*A31W<)[W5
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MP,FC.Z:J*9\$L@T>W8^PRZ8C69O][%I1HC2?][*!%"] :>QI2'M"_QIF2_0
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M J069=0@#LL!D.V?1\:TD'#'3YPAZT8P#4TMS&?"1P1QB!>:F;3*UA&*</(
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M3,LWN5P(M^LUJ.@=W+G^IB'@0>'T:T%Q>_>0;,\S#K]MY%8)I N.OCC<HWJ
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M/^H"7"=L%R/5HYA/<CV+-N6"<J?F3^MJ6=I_=W/P[@JBR>#HR:Z2-&2UF>U
MVF3A3=)C:*B[DO 8N;B/'!#N%4EX-QS3P,XZW#;'Q9:EFG53!G^[V7V]8Y;^
MI"PI(/&ROJS:QG&_OE:([E^*?\)]@R4FJDL.!950N<;(12B_B2]$QB#D<7UR
M=#4F[L0PU[SU^7K8<([<2UB?*2,Q?\Y(A=)/FSEZ=+8DFA^K.<VIE^ $JNFB
MHS*W;;->[_I"\E4$\,-VY?COR*2Q"YM$PPI_._,#N9)@#M90R;,W4?81]/HT
MWB#U/QS#L'[;WV2>T'O<C/$6I^-L[QQ]N:G7SETE3-,RZ/82+9[AC5@W=?R>
MX:AS6QTN2^6GK43(QT=KSW[M;3MZ-:L%_Q"#$/8<%M&\?/A!F9;M\_V31RK3
M1ZC+?T,[&X&;'AIGMU@%Q='^OP5<1G OG>79PP</'_/MIS@&WP= ^MTUF\VN
MUB*-B2?/"8A?IJX=GH -(L9GBR*0VD2.1N9BFR*:0/K_I%@_3/&\6$<CFF4@
M-T$)YFB23NMEA!YJ7K7SW4:./@\*PT;@Q5R6VD)@8 XF:(/"H;M/(JQ=[?NS
M46[1@NV24PKX,%,'*B'DOP<]T_O]J\B@.5P^ ?LAY]!BUZJ/2,6JA12=N' >
M*%4.5BY,!F@]L!>FR/D3_/" 'R7$)P#O_-;S$%(TA&%UHD+G(0H^AHMU@P$>
M>&PL$5;BV$@FF!$P?NUYO8C.C-$[GW:L&F7+%[**H3SJ(E#69QBL5<HS]W;F
ME#'].:.&5<FWW#';[* H[)/[*.P@"OOD/@K[&8OU9+GD*.S[XF/IND..I#G/
MOGJ0O7OS]^Q]2XW"K[._E^ N@DW[*L]>OWYNT'5DER9B:HILKCBJ"2_%8.>N
M#;K!FK^B0O=<[[XLAU\RL*W!(R%T&<'>.^GZH+]9[#!(,V/OE_$9J/BHI2L.
MEU8@2[X/[CK\%N5E@_@>W =P'TO[H1:_C'</=2+MI TII8'! !"')S .C%V
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M2BI$Z*("3E[BV;J+[: G?4_BPMR6YSU3E@H$]QW2&?N++4'")GUE(FZ$*(.
MAU\+,PP*Q%'1\Q4BEZ9"<!G@Z^!Z@C/Z@W?G7[D3YQB$1*>.BA++3&)4#,11
M?&N*WQXK(QG=!LM/K Z9D#IPW0;Z2UU)K*GAQS8$3><KP>%@#1O7O#&N0.1J
M/>1GPC\H61-"Y(1F7T":,-@KT@$@*M%)C8=>.)[Q#5]_OBQ/NGE5]1T[JJ&G
M[8)"G63EPN5#Q-VRB0GLL>REJK4VDS9,92=5:?QE[H1G2$UH/[+OIAZLA"M#
MW.!6RD\Y+"JU*WV[ZR^6N[5E)D(W9M5P6;65&HZ0XX;/*$C?L2?>:,4M1P[O
MF"A\>9I1U^O+DOI2QKQRI^AF1-D-^2H'-O#DRG4;B U*TC=W:RDG!=U_(=67
M9\8ZQ[HI<_F=NUIERD\-VD*P1MZU!BF)[2>0#(O;^MBJ%-M>CN!\C)ZM?))9
MV>3].853$&Q9BO=):^;QKV]=Z=;;=-P<U7[0$-%T&C2I9+R1N3X="W$&>&E\
M#6_BV9</'=M8ZMW3;!(AEE_PY*ZS-[18J2:J4WYV4)RCF&78VNA>:^$;Y,<L
M/0SSZJ*L'928N[5P49S61M* D_1H%COC^@=TA(/0LD;:EQ;;.I<4D'0!>&X#
M8($42B\ R_)GQV5#358<8YLO2'5#Q5X$G #3L7HY.CX*7Y</>_+16C'UJ+3.
MP@91B6'E?O5(=]N%]5E;'!1V"*&KP)T0L@_\0+O]JXJ3-&>!P=75Z!M=VE=N
ML%SY$CSM *X:XHH9BS%"2>7B)J:$5,Y=?+0F()N2\EU@2^TK;)"!TIE[O@CM
MN879G$"3(@K@0XED"W*.$ ? AA*G JBR+/96Z'^X![;CD-#\<0BJES!T>K4\
M R&> NFIDKI7Q1Q#G6&[/02TFH>PE#UUU+2)F@*2M4!4(DFY65!B9S1U(+,]
MYS'N(\T[S@:M3QZ#O%RB!8YB!NZB_2J64U,/!/C2]IJ=8>Q K0>/"4;[A!$N
M08Z R4IN!10_T$W'1QS%98%B D?<G. Q/H?DV%<: F\Q,P:VU;E18!'0L4=H
MZ;*A:@P26GX\-5+Y[Q5;2LVHW";-P=]);!DZ<LV+0FPH>-<MI+XI),@SC"2I
M,(4NZ="M8<F0.A'>W%A$EI3FNZS**V$(9,E.+1*L#7-'\KVOEOK7&0LD1FC5
M&4/7#[MNX)92=3=Y\TEF&4RHK;73B-Z)X1&M.KY<Z*A?3D-B'3KJS$-*;3S&
M'C*XNFY_DFUW'2Z$B.]50_MI+13R0GSF&TFX5VVQI9XC% I]_/ Q$2NEZ.X$
M970YE;:[V@/+=^H1&SQ,!*34X<!<088=TT)XCR+4<YBMFWI%4"QC,YBF/LX?
MV!9P,TJ]*]$41Q9;]OCLR5X+T@&63V'3S,3A"NX)WRR<CMYZ#28-UQ\-F6\
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M*F)<+._EG/E<J;3.)SQ]#1OW8:@K<L$T&.S;%(J>8'9/8\K VUL)4 =@%%\
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M11<[N&\S1*CGPH"Q$>S_C--LP6^&D#.MS'&P^.AF<U6<LKPQ/-=>2S="7&"
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MX6.U(U[56M>3PMNKI' M*;R]2@H_8+%FL'?9?6LY:!W;EV.O)C=!@5G??,[
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MJT,NF^W!".F.L'--U856#+->'(T+>&Q/1D3-95<%"=:UP'P987D_[DQ5'\-
M+802*/63.G)?TPDFT;F!6K*8HWTA!=7<J-K>B#VB<_PN/-+)1@*]*6I<\B(P
M?ZW+3.O92]J,];6-O4UYJ5*%H[E&?3=-5[Y:-C&;O!.!./ZEY7_@0EA^3^UR
M_IA4_>2_ZVN!YSLY)VC*+."T]-10R'C3SY3J@A;G:3_M*4=*+9>R7Q&Z73;<
M4@.BZ8CCY).Z$\[*9+B^9I9$[50Z'!>EDO/\"M^*Q<..88)!4Z51>HR;I+\L
MFUN]3Y_#\< S-$4P>5AI+(ZT-LXFFWM,J?0GFTG#Y,]L.!U&):PLO4^\6NR=
M[?6T9I8.YZ?:&E)?^7#X\7B7=PUC5V+7[9Z2LJ<)G:&9 )()+5/4)SNYTL=[
MGZRX0=HG?#D,UL;<GP31UT+Y#&<C_/T4_E(:'BGU\Y0JILQ R-N>EA92;GTM
M_'XKG>DH 2M?G>VINF @01HK_Z"'<+U.U@!:#Z;Y&1;LHAR87D'#NNQ;^I>>
M6T$H!-?S*WBEP.8]V!3E378&D/4:Z639W)6TZT'HS.I\]:Z\_A"P_(?%B)D9
MU7<ST*_ >Z \E>JFL_>=*I0YF_]70L,3URI4WS)&2HUN#.C4=M8@(E0*0T)J
M FD+KJ\I8Y"KYSR_2LW"@#P8/'7;(;=DEEZK:/FS5;2\%BU_MHJ6/V"Q!CRH
M4__H@\TAHURQ"'-M4[\"FV-SHUXS(UT4>@$K(^HKS5NFJ.]__/#IXZE<@:>7
M*8Q"2_F3=] /99MI\(T3T8_@ON;'[^%Y[VXQG!'): ;W^M]'."-RHQE8[W0_
MX8RH.9K!-6$3)YB\3!<'U*O,#R2OCMCJB*V.V#?4 WZA7FIUSO(,W"%S)/J-
MMF^TO1W[!X8VP'C4Z(_;TX68R%A8JXE[L9F:XPCP33?QR!AY'I($/P.; W4W
MMBQ6LY$66ZO&9W]6I6RKHV&AX6_[;%PSF+Z^MI"S40^F+]G1&'#6ZC0@YU 8
M.GLU&:&@X3"=: 913B@@;@@X\*9$TPDLJ!MN.$5@!)%^XS QUWFW G2KW3"A
M!VL$$CR5$)NOW$I1F^A03S7.\,)NDKFG13GF-[M)6AV393L%9YMHFTPDTVN]
M3L>6&N(B84W*R-H]3O(+A5!T>]LGSY5A7WX%#)3[\NEHDE$RO)<7A.VATP;.
MP-3O=;>[KG/DD?G9'K<:)]8-19B[&B88M\/X4H,1AWD)MPG<3PL91 "^%'6S
M'C[1H6QFN)A RSEIA'K-L"W(B;[@33RK:"<4T@I4%4.1K?H_-R<&I1/*6H9R
M7D:+,4'?$%0-3PN;_HRVJZ"=U5__$*1Z6%X\*%S#I^(<;X[PZ1BK!H0(YDU,
M17NH>\'3>TNF'K9WL.")<]BP\)WUM5T04=$%R1 (5<QG2]/9&HUNRSN,'K'1
M4FQE^V&YEE79!/1RR'*Y1RS6@HQWLBYFQ%0-U>XK\<9H?HH_^ ?TZ&@OCG8G
M"*U4J&'\Q$AU>QK.Y'GT:U&J\W=:0O7B'H8Y8YSAOXORJ_U)W;);6ULO8WK/
M#U%W4"K]KM;@'SUX7X6OZV0%8E8OV>YUG=T+**'6>_<^A\*O?Z*.IY[.@S+K
M1?]*1M$1:FK\9*66_P_\S#^V7V_EV2"M !M G;2.TK_T/36E7N<B&76@@C_X
M,6YG[A7CC+HK&1#)7@#0'#7)(,NF;\E)L?F#NKV4 HY^Z41'17J!+_O?%)[T
MSTYTTH.S7=IQ]G/UF7_ ?_+D$EZ+G_]:T>?^<89J 'Z_8$5Z7Q+3.D'R?)4@
MJ25(GJ\2) ]4I$TX,V@'8),:&@*87C9V &D:;-%D+YIM.%TDI6WU"04VELW8
M>H;&ULD4^\R+4E=E5H#"6ND>C'K_A-J+<+%;-N+F-%AC1G"@R#)B.G8S"@1A
M[,Y-W$L' 7FK:BT)E1DE#8(&:9")N1O![U7]\<L[$S> ;F2.8&%OY#FB>?T)
ML0$N4QZ2%6/K-)7M*<OE0C-'MJ@)%0,5PN#$NZV<TDC.B%OJRC!..I4^=O3>
M ""4J"24(\NIQCUTFF1MJS%G+Y!5ZLJ"/9(A3!7(HN#"<[BUKQBH9#0U[-8/
M7%^S'3$3_M'TX-0BN3.>;1IR1*05>T2LR\DQ1_TF\+Q3J@:C5<=,0#=E(8._
MF*HRR+40SI[F]Q)"22@RO/":E-X3W%&ADR#XN;>UNFFOCPAL'M-$!-@!%^DH
M05TEM!(Q^5%;4Z"(S:-Q]%=R1JTIXM)TT?$G9 XQDP!F00V'.#:GR1M>@+*U
MFX;62\Y#O&!]S2 =?P1+SF25H"^!3C(FQRQ%C2R8"7GJ3:=Q+FRN 444R:U:
M*!\I<>K1(I?K+3AT!.<(-AH0O4TR&&0Y0!3A.)P'ZJ$77=A^W:_-JVEB!SR-
M9;NIGN--M=N'3W'^#\0/PSW1R3A76V![!@VZ2L^ J=@( 0>O<Z2L*=.G&IQ=
M%SK..7X!H1-.6((#Y$QP#1F"HU\EQ"]S**RE?_0S$#P"OM:H\0CBXJ)S^KA0
M4/X(A=<8\5HV>7B!\G"@]"PP@8@ WAY=N\P%L*O178+&C(<7\UGY+O0'#C\1
M$6ZMLQ-*](HSJC(WY "GA"]JTPJQ\&XIM)OB:&L9%PM'782Z5:LIW#TI(DUC
M5XA4:EB)"LD6>XMR.? H+:985"Y3,14S(NN4'.FK47JFYLL**XA QDE1@OTU
M)M1AR_,1TV4T3*K>% J>XVB0#D'#I?SZ*3SU+,61F2L(JO:G<!2,A9=/83(:
MJ;K KZ,6)]24BNV\<Z+QK>KGUT+3UZR0TEYG:@W5X<,XAK]#B".'W6$91S 2
M<BOX>T;R3+6]L@Y$<Y@WFAEV4:>MX<TD. ACQ$9LT<=+U][F1;=*RPO=C:M[
M;/6(I(T[YRV7D.:",F]8!ZC^-?!*Q+KNPYKY:#_+IJ5>HI9"VP>*C;^,N ."
MBVXPO,U=[A?J@7WN")EZG].[QA(.8)>E.M/)^#S6>(6$_$(F<[-U[RLI$8H3
M@BR'$AX(,]"U'([1%^XL,--\\VFX+IC.=3$FN,!ZTC!^."MO=?,T)J?"B:,*
M]#_LN"?(\VQD&G2J: /M/#@%]3\B "(HE#K_N#*2:1CHE-A1+-FY:!6??+&*
M3];BDR]6\<D'+-;;KU#=7[^NZ@:1-J6;J*N&07()&X4#3O4\/EE@>7)IH@W8
MP0+_L)DX:PW;\E#3VZZC:"^>;C_?VM9/T5\V:;]/UO=U@?^RLDPOBAZU) &B
M@S(JAQGWRH!Q;$(T#B,6O^<#M1B103QATK;2MN6\+X@!5WW\EV2D'+P)(N71
M"/CB,F-E0T_=/]-RS,4<9(>!3V8I0#A"8''P/&J5^N6$H65E>U>:Z<NA7$#C
MR/]*]XJJ>X/]QTVXEZ$6V^ZFPQ"!W@#$_SQ<.FMQ>M/%,@\]4[;WE"E=TF7E
M@B>:9^ N8+49V89F.Z'4"5@*F--V)J(SBL=P2&BF "!&TNK+@?M2[!$SM,(8
M#,7Q X >%KW16B!$8V%H#1MG[W \F=@L<'F(=W* #&I<:;;Q3:=+D5FWC*YY
M1$@YHTF,L0D6SJIV4[ L=3I4NN?]NX,$$8WGN)5@\0 H'^T8FDU,4PB]J&HE
MU1__ .UD.%\@NN=*B'<6"HU@2VB*K>PVI?;>+QF4S?9KBF,IAVS4HQC@AZP_
M[65@)1ZGU&5:G6=C&\PROI0-9HEZ%SKMRU?-XO5QF,94<+=12W'#-$,H(JB+
MDMFAB:/FZ>@,BQ.H%7W*W(3@LNL6".G)-G!0UOO6D9;)I=GA^YGU9B@!@HI@
M5$0#+0LQ\=\6U O+#;.ED \UV\DE=N+.<+?%NO20XJH?N LT/\[UKJW@E05W
MO( 0TU ,7LT]C$FS^Q8(P(/_\@+>4%7)*+P8=:KN1=+N%\[$$4"0K&1,C!V#
M*%5^Y)34+>RZ$]7S?L/: A'9*MON$"NE7WVMM.FHDV\MQ &NYQ;RL&P;UG,W
M3""=L+#7<TB8"82LD<X*4>! J:;DC.UXN/>3/J$I,/B"W1BJIP)C+1M=%/D%
MP<R74!-!;R.::X9E)4@)+TMGU$_MC$+NTUCS1$5<4?$S(R[K-^$CY+#J8.\7
M63F9I@8XM[V>6\9JO[XK2&QJ&@S]6;:F:V!6$' "Z2#8 P:S=@LOP!F"\ #9
MC69CHOZ421T9>=A\1@F3^R'/%@DEB_']2IX$R8B&Z2%X28J7T\^;@;M7W%E$
M:&E'JM0B&M-%:>E*$7HXJ2H Z@1]Z,^+OR$Q-+D^ NU@'U+(.L;5I.A]!78D
MA&L!2V&$/Q&E>,I0;^JR5>JT*/W4_BK,5P_SO5R%^6IAOI>K,-\#%NOM-XQJ
M7"D]!VA9NZ,DOZJHH@91H=1FS?'?:HK2^"4E/U9I,GPJ7:_FMWV@+)B8G*5H
MGT&@G\P,@1'T,XR1 8@P,5@FHZ^@QZ#DH-*=<UB08/M> =XX09VK88]TR1*B
MA^6(2-83Y4(-4X&61G\N>!E!-\Y%EE[28S$Q8JLZ21&; 9<IA6[Z=B#?0VR$
M@)/LNI0I$.($T]?*_;"V#GP9V_ MPH\PE"SK (V/<8EF+* ;Y/0#*WW-!8V1
M(@IK7>?Z]GN.9E_FP88H9;L/U'81QA*;;-S%CQ5,)31(F6DC'Y)Y*RV"K9!4
M(Z3EL$+67EPYI$@+K>63D5&98T<7<,D=*-%"1- X#!'V=(^59V$&#U/;C0,:
ME%FG$YU4:M^$3#H,1PC0(&,J[Z32S :PG!I=6/V_0X(BXH'B(1";5S8>K!*7
M*CLF]8#EMK@<F7(BC@*;?S(+M-)=Q5!74N!ARPLBNJ[.U1E1Q[=B7R^#1&EW
M8JI();2>J9-;3MMEAZ#K]VQ(B.K+UM>N5Y=!*)Q<3'994'T&<C';!\>1-K]E
M?XQ-12<0#L[4- !CC?@'<]P>S:K"M4CT/=%34W"%#46JAG ]0(:(ZDMTJS/%
M@>Q YV;; 89O1.'E*^.4Z%#-E<F:JX\I;8+U;+;YG #2RD*=8Y)OW<LI2K'&
M_8%^M?@T%)AH&FME;%_I-!6^_4OGI*/\$DX2'9P<_O01&$M@:CM;6UMJ@3MG
MG3BZO+SL] MU0-2SL%4(*JG4[]*>\HSY=YMVK,X F0M*;[?8/V5@BN8K[N9W
M"@DLTF%_R@5$6 :07XDO<HV\J \PS<<#\L,BSE<M6['?#H'@[Z>#;)29AO$]
M-E-0/*F2Y@-:!K1&H2YDB!O#W;"S]?;']^_4(TW<A4#UW[_#OVZ_Q?@'UJPQ
M0XX%_U!O/ 8,R.=;+XR*A%^0NCVV-A.EY)S7J4N@ROK@AE[[?;3ZZJ71K'<"
M7FK/>^G[G_?P+.RVG2L5-=M+%FO%^)%FP?27,^XB%'VV7/4&5=_U1'0,$-5P
M7/<ZT?] )=#;:/OU\^V-KYN4MG.&OE?0T8 RSTEMS6"\E0QA#XH\+R[5%'X@
M_@S]L!X]9GTMQ>?H[R?:OH+Y9<#D,>"RW]C:NS230$8=)[+7^= YUA.A+=IY
ML=-YO:.V_BV!Y/NC0$.$AT! N[<_AN>O.L]P!)97PQ_%AY-#NPX:U>E6!_'L
M]4YG!_$L(5_J[*LZR<@Y>@S1%F];*6?1+(]FG#,$K]TH2?IPO[;C2*W9#JP7
M#'L[QD6QAAKG?0?>/$".HQ. HE"WCO('BYP MR%M/ZR=,Y)7?=5K8@E=V;"?
MHEVFG,AJ6N*PX=#J5BC'&9.HL!/;8(!#A,T^!6ZNZ/!0GXO]HM]_^D$]]&OT
M*RP6V[3'*7,P('9*I<R"$BH*)ISCXM='WMLQ"1QX_;+=23L<!.@59^)2TL9(
MLU142TK@PM#\3$[;X&&Y"I]-(J#BJQP'2A9KL.S/6?78)K6,F^]R+@3,!6WK
M:;?9:^Z)J/TMU)T44X&X@R"C:^G!#F??7W-(\[#6UPB^V .>Z3/@W^P9$O5Z
M> ).OL:;A1HJ0-V+8K)ZK5@-2#[A(JS0WY=,$0C:B6O+MH\'E$0U8ZW6?=?R
M/*ROS3L0SB7<T&1GPD3DR98]S&,&8T\01+2Q+*J>-E]!-W%41&=8A5!J^<?V
M5Q1.;S ]<P[,2V]^#EP!5ZX9]2BL!-S+:3QYIZR:WXX1SHC![3&X?SAB<!=$
M8'R?*SOB]SNLW!*#T9->Q+N<M\Q*6+U:):QJ":M7JX35HD5WIK8XU ZQ,MP+
MN!64+P2I=:B]KE+B7>'0F5LYU*:J+([&F-. N!?D['M(<L#$">.DEUJVJVZJ
M''*NMTXF.C:#'#W*;1B#T8RZ.D^QL; 6P$P,9(1MFFPSQ-M3T?C?9X#V*A<_
M3P>3FDX^W7U_=!#M'1P=G7S>W3O\^-/?GVP]P7]_WMW?U_^^]G NL_[D'#ZZ
M]9W1&KTBSY-QI<Z,_ND)BOJ/I\?Z!1=0^]!+<CUD=9Z>Z.-PNF_&KGXTOXSV
M/L'0/_[]R8X99WW6_X*8\:2$0.85D,3$^!#UG^.%#4%\<Z'O5>=Z[^A@%UYT
M?'!P"MAG=,)O-!#]*=[@EUO?/0F/S?W<\^]FR>*,+SY[.>^;M[68C0OX_NJ'
M\$?GW8:A@7]??1\=7RD+\B?HRKY:S SHZFO[Z84/#T,_[<?W"]"H@7K=9Y+?
MQ8SRQI]>]&G?W=L[^'QZL&_)FQ'E]1L._;>-9Y"IJ_HIX3DS!, /]S.8>]R4
M[==;T='AAX/H9._PX./>P8GZYO'GSJVOP\,5W\7HUQ\/4<5*Q$@*72Y,SUYS
M\LY %Z=MVWYZ[SQ+!]$!T7*J _R).-:]H7Z/9N2[Q9JN=_FJ5D[UZT6YTFV\
MQ4?AH,YT]!<@$NXKL*Z:XBQ?WIWL_7RP_T7Y2MN R#?+1^Y"]=)-7TUA]:)4
M4YZ.QVD)R.H-_KKDX,$/]%/E,2>$:#PJ1JE='J37N>_Q?GF'J3N(T!WM[AW\
M<O#Q='WMXZ?3P[T#6M)['=Y?V"_V7*:MSJL7(:T60BC]4*K#U>XN"'W]-UJU
M1?XW^OT;/=<V\]KKK1:E-J_38K4HM7F=4$;K&U;&24CM4@WS+T1$_0FJCI6G
MBZ7!.V]]J+<[,\(>/+#R3^I') U9< _Y?<[YL\-"%J#_,F6MHC'6PX5,HY,$
M*O!V:X%I]$^S@?H @^%'>T4Y[D0;\"6OO@W#UUZAT*8-9YOJA*.CO6C#_:Z0
M]=H#^EB<LSL]4VL0;3^+HYVMG1>! 0C:0/<)<72HFQD89'M]S6F7D]'W0-=?
MFN?*2H#U_2WB__V.&%ME#>_6%.L[>);11B(+T? +9K2; ..= .H6,HTSUSRR
MC,/#__9;]#ODH@E>L\,;59US4ED)#$Y&1W-,Z<='9G<T566PY=EHJME_?MO?
M/3WX/?K-8(=2MRZPR_R^8A=P';HW*X?N,2/UA_VYG7G^W*V]=:&5 5^8CDC#
M9-_Q+'E/%YI&UA,U-])B9OAX/,6=[>\:YE@+2S8]XM6;ID>TBQQ^BTU>VY%Y
M)GCH"[<\%"0F.NX8;J)K#(H6;)<:XR"_==>QUJ9#50LL8;D%@" _K297D*KK
M%]-NGM8.^\PPTRV?><>27!W\VSKX?O+W^N>^EIY%ZWU[^VU$ OY)&;E)&_F6
M&^F$A^O!X6;#8>X7D\EP4B+VMD?91L]:D"S=U5EI8?4^WUI9O0NT>N_'QMWH
M;CY",[=V487"_3K]OK[6F'^_RWOK!H-=U)5Z@Z']]A__?[^OKYW\O'M\<*+D
M[<?WH,/E?RE(M?O3\0'F>^B7>GY:'N]RCBR6BSASL!H0M/K/?^YXOQ9S=_B$
MJ7?]OA#EZEV_LT[H&B&?ZX(MR3MZRY$R:]0S_B<9CM]&-F2^F)<OYBT-8>LX
M2@ J(KE,$'JA''->?'W-#R?7H@<VF#PN"VS*=W!0W,B[B+1CZPU!IV8C[D .
M1=QCBG.OK\T+=*OKV_UF?81MJLIK4?BP[V0>BED$I!"BF#($Q7WZY,FY@P+C
M\-KCE'OG:1_P!HAZ*#"US].R=YY B]2)>8X_E YPC^3(53_1I.@ZN(XU^C'O
MA!=Q]U,< LW/]#)RFS: 4:KUFU9FYSJ/Z70XP-J6FU!#_[KKA'2D>B][V#:E
M6<9T%RA":#&TOH=>%"-:\5DZJ@,1 DXA)#(18G/,&R_E!\DH]2F%H\&'"/,X
MB+O4PUX-  I*D8YJ<N7UT3O\)XAOHO,C/A!,N*,UT\R*@L$QZ3,4JH-K@7A*
M+"N17&"?5#&RG(H6;9(97LT#)SS5P$0L_@H@TR#J@JCF;9R?[GX_22>D[R?1
M/GS>F43@D#XJP=\=$;>4W/$P+0$BQ"? 5S;.'0&1- 7<\@Q6,#>6QAYPO/I\
M0*/%>JVQ\(G6&;Q9 :!3Y[7/ ,3V4M\^6J8'6:X9]?AP,<;/H]JWDS87K19D
MHR>:+UL&FP(K0&J8**!@/#9?AH:==Q7&!';A-A6;[QIE9Z#JC%)L$AF'ZQDY
M9:'H@Q0($X3JAU+J6)YK:H)_S ?[8S&!,R! PZ]\[JW Q5:4,^\"@M,OKUP1
M8,[2JF[]4+A0BYQ; 0!M@T%4O^)R!(!]FE/3$O?Z2'AYAF_EW<9[BH2A0N!^
M<PL$I:?HJ1\M]:,FM? Y+!Z32+2*<6ZO8IR/)\9IWE+K&$9+TD=1PHY/MV48
M:/RX'5@]D=$_)],2$>.G 'PAH?*("E T  </E43<)M#ZN2;W?+,WOEY[<0VG
M7V)AWLNA_TLER>8T<[E1AU P62;,;B?)S!-]T91M:]-"^RU?]AM\;SE=[H2>
M8?N?5MG_I20#W!G&T>%O;Q";.>U[FR/VC/$L;UC'<-?_?2 KI1O79@C$0]CN
M;RE&N:WQM55DN\BOPSBN>)WTN6OX7H9C@AO8,ARY+</W,Z1[W)PZ:L,22?#J
MTFA[:?Q5]^GNU?F=5\H]( =W8;!>*P?W[K=>U'&;8)YR3#V'<W%EUHN1<T(
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ML.JVYGY+HC/F[O#T3YAJI4XZ=&-'LQX8\ZPXY@J=0-Y"49A,; F"$5=C92^
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M**7'"&$@_J\, SF#O(\UE*NGWO[]^T_[_P9Q_O[GTU^.U __#U!+ P04
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MGU;K[QZ*GW*FK ,<VMC_C]+_R:KQ-2UOTY]MN;_CHC_W^A]02P$"% ,4
M" "WJPU;O0XTRLX#  #I#@  $0              @ $     871N9BTR,#(U
M,#@Q,RYX<V102P$"% ,4    " "WJPU;$FS'!  )  "4:   %0
M    @ '] P  871N9BTR,#(U,#@Q,U]D968N>&UL4$L! A0#%     @ MZL-
M6VW\7O?P"P  $Y   !4              ( !, T  &%T;F8M,C R-3 X,3-?
M;&%B+GAM;%!+ 0(4 Q0    ( +>K#5OR,#-A2@@  "YC   5
M  "  5,9  !A=&YF+3(P,C4P.#$S7W!R92YX;6Q02P$"% ,4    " "WJPU;
M\4R(& <<  #[D@  &               @ '0(0  96$P,C4R-3DV+3AK7S$X
M,&QI9F4N:'1M4$L! A0#%     @ MZL-6XE7D>L0K0  _+@# !P
M     ( !#3X  &5A,#(U,C4Y-C Q97@Q+3%?,3@P;&EF92YH=&U02P$"% ,4
M    " "WJPU;+(S)8@$.  #U-0  '               @ %7ZP  96$P,C4R
L-3DV,#%E>#4M,5\Q.#!L:69E+FAT;5!+!08     !P ' .(!  "2^0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ea0252596-8k_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20250813"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20250813.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2025-08-13</startDate>
            <endDate>2025-08-13</endDate>
        </period>
    </context>
    <context id="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-13</startDate>
            <endDate>2025-08-13</endDate>
        </period>
    </context>
    <context id="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-13</startDate>
            <endDate>2025-08-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-13" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-13" id="Fact000004">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-13" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-13" id="Fact000010">2025-08-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-13" id="Fact000011">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-13" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-08-13" id="Fact000013">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-13" id="Fact000014">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-13" id="Fact000015">2875 South Ocean</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-08-13" id="Fact000016">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-13" id="Fact000017">Palm Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-13" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-13" id="Fact000019">33480</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-13" id="Fact000020">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-13" id="Fact000021">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-13" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-13" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-13" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-13" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000026">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-08-132025-08-13_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000029">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000030">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-08-132025-08-13_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-13" id="Fact000032">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
